Animal Research on the Front Lines
Nov. 24: ‘Twist Bioscience’s COVID-19 “nanobodies,” inspired by llamas, show promise in hamsters,’ FierceBiotech
Nov. 24: ‘Evidence builds that an early mutation made the pandemic harder to stop,’ The New York Times
Nov. 23: ‘Oxford vaccine: How did they make it so quickly?’ BBC News
Nov. 23: ‘This Gates-backed, MIT-based biotech company solves a key vaccination problem,’ Fast Company
Nov. 23: ‘Endangered primates face high risk of catching COVID-19,’ National Geographic
Nov. 23: ‘Can dogs smell COVID? Here’s what the science says,’ Nature
Nov. 23: ‘Coronaviruses closely related to the pandemic virus discovered in Japan and Cambodia,’ Nature
Nov. 23: ‘Incannex says cannabidiol-hydroxychloroquine cocktail shows promise in new animal study,’ Stockhead
Nov. 23: ‘Pfizer and Moderna use mRNA in their COVID-19 vaccines. This never-before-used technology could transform how science fights diseases,’ USA Today
Nov. 23: ‘The Egyptian corona vaccine reaches its final stages … and the National Research Center: We are awaiting the approval of the Drug Authority,’ Youm7
Nov. 22: ‘France finds COVID-19 in mink at one farm, ministry says,’ Reuters
Nov. 22: ‘Denmark says mutated coronavirus from mink farms “most likely eradicated,”’ Steelers Lounge
Nov. 22: ‘Machine-made molecules fight the coronavirus in lab animals,’ The New York Times
Nov. 21: ‘COVID-19: Phase 3 of COVAXIN to check its effectiveness to prevent disease,’ ANI
Nov. 21: ‘FDA allows emergency use of antibody drug Trump received,’ The Associated Press
Nov. 21: ‘Steve Ackerman and Jon Levine: Humane research will help stop the virus,’ Wisconsin State Journal
Nov. 20: ‘What is mRNA What you should know about vaccines – Nuremberg,’ AlKhaleej Today
Nov. 20: ‘Cats can easily spread COVID-19 to other cats, and possibly humans,’ ConsumerAffairs
Nov. 20: ‘1st animal study in India on coronavirus moves to its final stage: AYUSH Ministry,’ Press Trust of India
Nov. 20: ‘Poland finds COVID-19 cases among mink farm workers,’ Reuters
Nov. 20: ‘COVID-19 outbreaks at US mink farms raise alarm after mutant strain spreads to humans in Denmark,’ Salem Statesman Journal
Nov. 20: ‘Minks spreading COVID to humans; Oregon may not be safe,’ The Corvallis Advocate
Nov. 20: ‘What has to happen before a Covid vaccine can be used?’ The Guardian
Nov. 19: ‘Covid: Oxford vaccine shows “encouraging” immune response in older adults,’ BBC News
Nov. 19: ‘New findings support current and planned clinical trials of Janssen SARS-CoV-2 vaccine,’ News Medical
Nov. 19: ‘Global foundation awards Texas Biomed $1 million to conduct large-scale rodent testing of human monoclonal antibodies to combat SARS-CoV-2,’ Texas Biomedical Research Institute
Nov. 19: ‘Coronavirus latest news: Results from late-stage Oxford vaccine trials expected by Christmas,’ The Telegraph
Nov. 19: ‘Wayne State researchers identify cornea as a potential carrier of COVID-19,’ Wayne State University School of Medicine
Nov. 19: ‘How a medication for OCD ended up in a COVID-19 trial,’ WIRED
Nov. 18: ‘When will we have a COVID-19 vaccine?’ DW
Nov. 18: ‘Two K-State studies focus on SARS-CoV-2 transmission in domestic cats, pigs,’ Kansas State University
Nov. 18: ‘2 K-State studies focus on coronavirus disease transmission in domestic cats, pigs,’ KSNT
Nov. 18: ‘Could the next coronavirus outbreak come from pigs?’ Massive Science
Nov. 18: ‘Engineered antibodies to combat viral threats,’ Nature
Nov. 18: ‘Pfizer and BioNTech to submit COVID-19 vaccine data to FDA as full results show 95% efficacy,’ STAT News
Nov. 18: ‘In the lab, St. Jude scientists identify possible COVID-19 treatment,’ St. Jude Children’s Research Hospital
Nov. 18: ‘Cats can give other cats COVID quite easily,’ Veterinary Practice News
Nov. 18: ‘K-State studies focus on COVID-19 transmission in cats, pigs,’ WIBW
Nov. 17: ‘Immunogenicity of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaques,’ bioRxiv
Nov. 17: ‘How a lung injury study helped inspire new COVID-19 drug trials,’ Broad Institute of MIT and Harvard
Nov. 17: ‘Primate study reveals SARS-CoV-2 immunosuppressive effects for development of COVID-19 treatments and vaccines,’ HospiMedica International
Nov. 17: ‘Moderna announces supply agreement with United Kingdom government to supply mRNA vaccine against COVID-19 (mRNA-1273) if approved for use,’ Moderna
Nov. 17: ‘What is mRNA? How Pfizer and Moderna tapped new tech to make coronavirus vaccines,’ NBC News
Nov. 17: ‘She was principal investigator of Moderna COVID-19 vaccine trial in Newark. Her insights will inform you,’ ROI-NJ
Nov. 17: ‘Moderna and Pfizer are reinventing vaccines, starting with Covid,’ The Wall Street Journal
Nov. 16: ‘There’s only one animal that we know can give humans COVID-19,’ BGR
Nov. 16: ‘Research behind COVID-19 vaccine development began at Penn lab decades ago,’ KYW Newsradio
Nov. 16: ‘Moderna announces longer shelf life for its COVID-19 vaccine dandidate at refrigerated temperatures,’ Moderna
BREAKING NEWS: Nov. 16: ‘Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study,’ Moderna
Nov. 15: ‘This new COVID-19 mutated strain could be more infectious yet susceptible to a vaccine,’ The Science Times
Nov. 14: ‘This is the only animal we know for sure can give you COVID, experts say,’ Best Life
Nov. 13: ‘Shortage of monkeys slowed down Eli Lilly’s COVID-19 antibody partner. And it’s a problem for everyone,’ Endpoints News
Nov. 13: ‘India’s mRNA-based Covid vaccine won’t need ultra cold conditions for storage — Pune firm,’ ThePrint
Nov. 13: ‘Q&A: Minks can transmit SARS-CoV-2 to humans, study shows,’ The Scientist
Nov. 13: ‘UM School of Medicine and School of Pharmacy researchers identify promising new compounds to potentially treat novel coronaviruses,’ University of Maryland School of Medicine
Nov. 12: ‘International Ultraviolet Association: UVC disinfection and COVID-19,’ Health Europa
Nov. 12: ‘Matthew R. Bailey: Shortage of animals could delay a vaccine,’ Pittsburgh Post-Gazette
Nov. 12: ‘Vaccine works against mutated mink coronavirus in early animal trials: Danish scientist,’ Reuters
Nov. 12: ‘Vaxart reports more positive data from animal testing of its coronavirus vaccine candidate,’ The Motley Fool
Nov. 11: ‘Where did COVID come from? WHO investigation begins but faces challenges,’ Nature
Nov. 11: ‘Mutant coronaviruses found in mink spark massive culls and doom a Danish group’s research,’ Science
Nov. 11: ‘The strange and twisted tale of hydroxychloroquine,’ WIRED
Nov. 10: ‘Denmark rolls back order for mink cull amid legal dispute,’ CNN
Nov. 10: ‘People started coronavirus back-and-forth on mink farms, Dutch study shows,’ CNN
Nov. 10: ‘Testing begins for mutant Covid virus in Irish mink,’ Irish Independent
Nov. 10: ‘Pfizer vaccine results are promising, but lack of data “very concerning,” experts say,’ National Geographic
Nov. 10: ‘Poland looks into coronavirus risks at mink farms,’ Reuters
Nov. 10: ‘Can a nose-full of chicken antibodies ward off coronavirus infections?’ Science
Nov. 10: ‘Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans,’ Science
Nov. 10: ‘The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race,’ STAT News
Nov. 10: ‘A COVID-19 mutation belatedly forces Denmark to halt mink farming,’ The Economist
Nov. 10: ‘India’s m-RNA vaccine could be ready in March,’ The Hindu
Nov. 10: ‘Penn Medicine researcher laid groundwork for Pfizer, Moderna vaccines,’ WPVI
Nov. 9: ‘A coronavirus-fighting nasal spray protects ferrets from infection, early research shows. But it has a ways to go before reaching people,’ Business Insider
BREAKING NEWS: Nov. 9: ‘“Great day for science”: Pfizer shares early Covid vaccine analysis,’ FBR Blog
Nov. 9: ‘Search for a snakebite drug might lead to a COVID treatment, too,’ Kaiser Health News
Nov. 9: ‘Pfizer, Texas Biomed see promising results in prototype vaccine,’ KSAT
Nov. 9: ‘COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice,’ Nature
Nov. 9: ‘What Pfizer’s landmark COVID vaccine results mean for the pandemic,’ Nature
Nov. 9: ‘Pfizer claims 90 percent effectiveness, EU wants to buy vaccine,’ News1 English
Nov. 9: ‘Texas Biomed helps Pfizer successfully test Covid-19 vaccine by using monkeys,’ News 4 San Antonio
Nov. 9: ‘Millions of minks to be killed, as officials say they pose COVID risk to humans,’ The Beet
Nov. 9: ‘Pfizer’s early data shows vaccine is more than 90% effective,’ The New York Times
Nov. 9: ‘Eli Lilly’s COVID-19 antibody drug gets FDA green light,’ The Wall Street Journal
Nov. 9: ‘Validity of key studies on origin of coronavirus in doubt; science journals investigating,’ U.S. Right to Know
Nov. 9: ‘Do your clients have a contingency COVID pet-care plan?’ Veterinary Practice News
Nov. 8: ‘Researchers compare rhesus and cynomolgus macaques for SARS-CoV-2 vaccine trials,’ News Medical
Nov. 8: ‘Covid infections in animals prompt scientific concern,’ The New York Times
Nov. 6: ‘SARS-CoV-2 mink variant spreads to humans, raises concern about future vaccine efficacy,’ BioWorld
Nov. 6: ‘WHO looking at how a Covid mutation among minks may affect a future vaccine,’ CNBC
Nov. 6: ‘Nasal spray blocks coronavirus in animals,’ HealthDay News
Nov. 6: ‘Two Taylor County mink farms under quarantine after more than 5,000 animals died from COVID-19,’ Milwaukee Journal Sentinel
Nov. 6: ‘The WHO is hunting for the coronavirus’s origins. Here are the new details,’ National Geographic
Nov. 6: ‘Denmark: COVID mutation has spread from minks to humans,’ Newburgh Gazette
Nov. 6: ‘Denmark: COVID mutation has spread from minks to humans,’ New York South East Post
Nov. 6: ‘Danish Covid mink cull and future disease fears will kill fur trade, say farmers,’ The Guardian
Nov. 6: ‘How WHO is working to track down the animal reservoir of the SARS-CoV-2 virus,’ World Health Organization
Nov. 5: ‘Denmark to cull up to 17 million mink amid coronavirus fears,’ BBC News
Nov. 5: ‘Denmark is culling millions of furry minks to extinguish a worrying COVID-19 outbreak,’ Fortune
Nov. 5: ‘Pitt researchers discover llama “nanobodies” are powerful new coronavirus treatment,’ KDKA
Nov. 5: ‘Speeding COVID-19 drug discovery with quantum dots,’ NIH Director’s Blog
Nov. 5: ‘Exclusive: India-made COVID-19 vaccine could be launched as early as February – government scientist,’ Reuters
Nov. 5: ‘Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2,’ Science
Nov. 5: ‘Coronavirus: Millions of mink to be culled after passing COVID mutation to humans,’ Sky News
Nov. 5: ‘Spread of mutated coronavirus in Danish mink “hits all the scary buttons,” but fears may be overblown,’ STAT News
Nov. 5: ‘Denmark seeks to kill 15 million minks to limit coronavirus,’ The Hill
Nov. 5: ‘Nasal spray prevents Covid infection in ferrets, study finds,’ The New York Times
Nov. 5: ‘Denmark to cull 17 million mink after coronavirus mutation found,’ The Wall Street Journal
Nov. 5: ‘Llama nanobodies could be a powerful weapon against COVID-19,’ University of Pittsburgh
Nov. 5: ‘More than 3K mink dead from coronavirus at Taylor County mink farm,’ Wisconsin Public Radio
Nov. 4: ‘Denmark to cull 15 million mink after coronavirus spillover into humans,’ National Geographic
Nov. 4: ‘Continued impact of COVID-19 on biomedical research,’ National Institutes of Health
Nov. 4: ‘Prospects for a safe COVID-19 vaccine,’ Science
Nov. 4: ‘Denmark wants to cull 15 million minks over COVID fears,’ The Associated Press
Nov. 4: ‘Denmark announces cull of 15 million mink over Covid mutation fears,’ The Guardian
Nov. 4: ‘Denmark will kill all farmed mink, citing coronavirus infections,’ The New York Times
Nov. 4: ‘Denmark to kill all farmed mink due to coronavirus infections,’ The Science Times
Nov. 4: ‘The many model systems of COVID-19,’ The Scientist
Nov. 3: ‘Highly potent nanoparticle COVID-19 vaccine designed using computer,’ European Pharmaceutical Review
Nov. 3: ‘Nanoparticle based COVID-19 vaccine candidate shows promising results in mice: Study,’ Indo-Asian News Service
Nov. 3: ‘Scientists develop “ultrapotent” COVID-19 vaccine candidate,’ Press Trust of India
Nov. 3: ‘Will a small, long-shot U.S. company end up producing the best coronavirus vaccine?’ Science
Nov. 2: ‘Scientists develop a “nanoparticle” COVID-19 vaccine that could trigger a 10-times stronger immune response than the reaction seen in survivors and protect against future mutated strains,’ Daily Mail
Nov. 2: ‘Can a darkhorse synthetic biology COVID-19 vaccine one-up the frontunners? The Gates Foundation, Amgen bet “yes,”’ Endpoints News
Nov. 2: ‘Chinese virologist claiming Covid was lab-made teases another reveal on Twitter,’ Newsweek
Nov. 2: ‘How the coronavirus hacks the immune system,’ The New Yorker
Nov. 2: ‘Rapid method finds potent COVID-19 monoclonal antibody,’ University of Pittsburgh Medical Center
Nov. 1: ‘An explorer tours the planet of the viruses,’ Discover Magazine
Oct. 30: ‘Small particles, big change: Iowa scientists awarded $2 million in CARES funding for COVID-19 nanovaccine,’ Des Moines Register
Oct. 30: ‘COVID-19 tests given to cats, dogs, dolphins and more animal species by US scientists,’ Kaiser Health News
Oct. 30: ‘Texas A&M study examines COVID-19 and pets,’ KTRK
Oct. 30: ‘Scientists testing animals in effort to understand COVID-19,’ Newsmax
Oct. 30: ‘Hamsters and dolphins can get COVID-19 tests now,’ New York Post
Oct. 30: ‘How two immune system chemicals may trigger COVID-19’s deadly cytokine storms,’ Science News
Oct. 30: ‘2nd study testing a COVID-19 antibody drug has a setback,’ The Associated Press
Oct. 30: ‘Ultrapotent COVID-19 vaccine designed via computer,’ UW Medicine
Oct. 30: ‘Zoo Knoxville tiger tests positive for COVID-19 virus; two others presumed infected,’ WBIR
Oct. 29: ‘Primates also need protection from COVID-19: Calgary-led study,’ 660 NEWS
Oct. 29: ‘Mimicking coronavirus could be key for COVID-19 vaccine,’ Futurity
Oct. 29: ‘Gilead’s COVID-19 drug is mediocre. It will be a blockbuster anyway,’ The New York Times
Oct. 28: ‘U of C researchers say some non-human primates face similar COVID-19 risks as humans,’ CTV News
Oct. 28: ‘Exploring human drug for feline coronavirus,’ DVM 360
Oct. 28: ‘Controlling monkey brains with light could get easier thanks to open data project,’ Science
Oct. 28: ‘SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19,’ The New England Journal of Medicine
Oct. 28: ‘Argentinian preclinical animal research reveals potential ivermectin-based nasal spray targeting SARS-CoV-2,’ TrialSite News
Oct. 28: ‘Transforming coronavirus protein into a nanoparticle could be key to effective vaccine,’ University at Buffalo
Oct. 28: ‘Some non-human primates bear similar risk as humans for COVID-19 infection,’ University of Calgary
Oct. 27: ‘Vaccine developed against COVID-19 started to be administered to volunteers,’ Corona 24 News
Oct. 27: ‘“Every minute counts.” This immunologist rapidly reshaped her lab to tackle COVID-19,’ Science
Oct. 26: ‘Israeli vaccine for corona: The experimental phase in humans is underway,’ AlKhaleej Today
Oct. 26: ‘Ontario dog first in Canada to test positive for COVID-19, but researcher says there are likely more,’ CBC News
Oct. 26: ‘Could ASPIRIN be the first over the counter treatment for coronavirus? Hospitalized patients already taking the drug daily were 47% less likely to die of COVID-19,’ Daily Mail
Oct. 26: ‘How a virus can trigger diabetes,’ Genetic Engineering & Biotechnology News
Oct. 26: ‘Texas Biomed teams up with scientists nationwide to fight coronavirus,’ KENS5
Oct. 26: ‘The tale of a mouse-lab mastermind,’ Nature
Oct. 26: ‘Nasal spray formulation of ivermectin for COVID-19 shows promise in pigs,’ News Medical
Oct. 26: ‘Phase 1 trial results of gorilla adenovirus vaccine for COVID-19,’ News Medical
Oct. 26: ‘Study suggests 5’UTR of SARS-CoV-2 might be of pangolin coronavirus origin,’ News Medical
Oct. 26: ‘The global push for a COVID-19 vaccine,’ Technology Networks
Oct. 26: ‘Lilly antibody drug fails in a COVID-19 study; others go on,’ The Associated Press
Oct. 26: ‘Niagara-area dog tests positive for COVID-19 but most pets are still safe,’ The Canadian Press
Oct. 26: ‘Rare likelihood of pets contracting COVID-19,’ The Garden Island
Oct. 23: ‘DCGI’s expert panel recommends phase 3 clinical trial nod for Bharat Biotech’s COVID-19 vaccine,’ Mid-Day
Oct. 23: ‘The race to make COVID antibody therapies cheaper and more potent,’ Nature
Oct. 23: ‘Covaxin, Bharat Biotech’s coronavirus vaccine, cleared for Phase 3 trials,’ NDTV
Oct. 23: ‘Placebo group: What happens after a Covid vaccine is authorized?’ Newburgh Gazette
Oct. 23: ‘CureVac posts positive pre-clinical data for COVID-19 vaccine,’ Reuters
Oct. 23: ‘Vaxart: A strong buy for their oral tablet COVID-19 vaccine,’ Seeking Alpha
Oct. 22: ‘Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to prevent & treat COVID-19,’ Accesswire
Oct. 22: ‘Susceptibility of raccoon dogs for experimental SARS-CoV-2 infection,’ Emerging Infectious Diseases
Oct. 22: ‘CDSCO panel recommends granting permission to conduct phase 3 clinical trials of COVID-19 vaccine,’ Press Trust of India
Oct. 22: ‘Arizona based biotech company finds preliminary success developing an intranasal COVID-19 vaccine alternative,’ PR Newswire
Oct. 22: ‘Coronavirus: Which treatments work and which don’t?’ The Conversation
Oct. 21: ‘Where the Romanian vaccine against SARS-CoV-2 got stuck. “Some just don’t understand what we’re doing,”’ Box24 News
Oct. 21: ‘Animal trials of domestic COVID-19 vaccine completed,’ Corona 24 News
Oct. 21: ‘New study shows antibodies help in fight against COVID-19,’ KSAT
Oct. 21: ‘COVID-19 antibodies on trial,’ Nature Biotechnology
Oct. 21: ‘Oxford developed Covid vaccine, then scholars clashed over money,’ The Wall Street Journal
Oct. 20: ‘Fauci “cautiously optimistic” about safe, effective COVID-19 vaccine by end of year,’ Healio
Oct. 20: ‘Research in the time of covid,’ MIT Technology Review
Oct. 20: ‘Commercial antibodies: Alternative grading for research,’ Nature
Oct. 20: ‘Non-animal-derived antibodies: Pharma companies respond,’ Nature
Oct. 20: ‘Androgen deprivation strategies could help mitigate SARS-CoV-2 infection,’ News Medical
Oct. 20: ‘Veterinary experts offer advice after pet cat tests positive for COVID-19 in Pa.,’ Pennsylvania State University
Oct. 20: ‘US Army launches early-stage COVID-19 vaccine study,’ Precision Vaccinations
Oct. 20: ‘Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity,’ Science
Oct. 20: ‘Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,’ Science
Oct. 20: ‘Pennsylvania confirms its first COVID-19-positive cat,’ WGAL
Oct. 20: ‘Your pets and coronavirus, tips from an expert for protection,’ WOLF
Oct. 20: ‘Emergency COVID-19 vaccine aims to protect high-risk groups,’ Xinhua
Oct. 19: ‘Covid vaccine hopeful Vaxart starts study amid DOJ investigation and shareholder lawsuits,’ San Francisco Business Times
Oct. 19: ‘Use of adenovirus type-5 vectored vaccines: A cautionary tale,’ The Lancet
Oct. 19: ‘Preclinical testing of inhaled monoclonal antibody for COVID-19 shows therapeutic efficacy,’ University of Alabama at Birmingham
Oct. 19: ‘A COVID-19 vaccine is coming—will it be safe?’ Yale Medicine
Oct. 18: ‘Coronavirus could drive the last nail into the mink fur trade,’ CNN
Oct. 18: ‘COVID-19 vaccine company under federal investigation after allegedly misrepresenting its role in government program Operation Warp Speed,’ CNN Business
Oct. 18: ‘New research: Anti-ulcer drug shows promise in suppressing coronavirus,’ Express News Service
Oct. 16: ‘Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates,’ bioRxiv
Oct. 16: ‘SARS-CoV-2 vaccine development, access, and equity,’ Journal of Experimental Medicine
Oct. 16: ‘A betacoronavirus multiplex microsphere immunoassay detects early SARS-CoV-2 seroconversion and controls for pre-existing seasonal human coronavirus antibody cross-reactivity,’ medRxiv
Oct. 16: ‘High-titer convalescent plasma reduced COVID-19 symptom severity in green monkeys,’ News Medical
Oct. 16: ‘Sanofi and Translate Bio eye launch of phase 1/2 COVID-19 vaccine study,’ PMLive
Oct. 16: ‘How San Antonio researchers played a key role in President Donald Trump’s experimental COVID-19 treatment,’ San Antonio Report
Oct. 16: ‘Sanofi’s mRNA vaccine for coronavirus to enter clinical stage,’ Zacks Equity Research
Oct. 15: ‘Sanofi plans human trial after mRNA vaccine works with animals,’ Bloomberg
Oct. 15: ‘FDA authorizes Phase 1 trial of ImmunityBio’s novel COVID-19 vaccine candidate hAd5; dual construct is designed to drive both T cell and antibody immunity,’ Business Wire
Oct. 15: ‘Timeline: Vaccines,’ Cell
Oct. 15: ‘What it’s really like to do science amid COVID-19,’ Nature
Oct. 15: ‘Sanofi reports positive animal test results for potential COVID-19 vaccine,’ Reuters
Oct. 15: ‘New study highlights risks associated with the sequential infection of influenza followed by COVID-19,’ University of Liverpool
Oct. 14: ‘BioNTech analyst breaks down coronavirus vaccine readout timeline,’ Benzinga
Oct. 14: ‘Vaxart ups production as oral COVID-19 vaccine dosing begins,’ BioProcess International
Oct. 14: ‘Did oral COVID-19 vaccine maker Vaxart exaggerate Warp Speed role to benefit insiders? DOJ wants to find out,’ FiercePharma
Oct. 14: ‘Influenza drug shows promise against SARS-CoV-2,’ Medical News Today
Oct. 14: ‘AUSA NEWS: Army COVID-19 vaccine to enter clinical trials,’ National Defense Magazine
Oct. 14: ‘How anti-ageing drugs could boost COVID vaccines in older people,’ Nature
Oct. 14: ‘New kind of coronavirus that affects pigs has the potential of jumping from swines to humans,’ Press Trust of India
Oct. 14: ‘Cows to COVID: How a veterinary lab became key to UW-Madison’s pandemic response,’ Spectrum News
Oct. 13: ‘Covid: Why bats are not to blame, say scientists,’ BBC News
Oct. 13: ‘Why are so many minks dying of COVID-19?’ Forbes
Oct. 13: ‘Regeneron’s antibodies prevent and treat SARS-CoV-2 infection in monkeys,’ Genetic Engineering & Biotechnology News
Oct. 13: ‘Favipiravir at high doses works to curb COVID-19 in hamsters, HCQ ineffective: Study,’ Firstpost
Oct. 13: ‘To end this pandemic, we must trust science,’ National Geographic
Oct. 13: ‘Possible safety issue spurs pause of COVID-19 antibody study,’ The Associated Press
Oct. 12: ‘Hong Kong scientists say anti-microbe drug successful against coronavirus,’ Agence France-Presse
Oct. 12: ‘An airport in Finland already uses dogs to detect COVID-19,’ Entrepreneur
Oct. 12: ‘South Dakota developing a vaccine for pets,’ KTIV
Oct. 12: ‘Experimental COVID-19 treatment given to Trump found to relieve symptoms in macaques and hamsters,’ Medical Xpress
Oct. 12: ‘Hydroxychloroquine does not counter SARS-CoV-2 in hamsters, high dose of favipiravir does,’ Medical Xpress
Oct. 12: ‘Nasal spray COVID-19 vaccine shows promising results in mice,’ News Medical
Oct. 12: ‘Stopping lethal lung damage from the flu with a natural human protein,’ Ohio State News
Oct. 12: ‘Lab-made “miniproteins” could block the coronavirus from infecting cells,’ Scientific American
Oct. 12: ‘Danes start culling 2.5 million minks after virus hits farms,’ The Associated Press
Oct. 12: ‘COVID-19 masks FAQs: How can cloth stop a tiny virus? What’s the best fabric? Do they protect the wearer?’ The Conversation
Oct. 12: ‘Inhaled coronavirus vaccines are under development — and could be more effective than an injection,’ The Week
Oct. 12: ‘Thousands of mink dead after COVID-19 outbreak at Wisconsin mink farm,’ WORT
Oct. 11: ‘Inhaled vaccines aim to fight coronavirus at its point of attack,’ Bloomberg
Oct. 10: ‘Coronavirus | Antibody cocktail given to Donald Trump may protect against COVID-19, says study,’ Press Trust of India
Oct. 10: ‘At least 12,000 minks in Utah, Wisconsin die after contracting COVID-19 from humans,’ Tech Times
Oct. 10: ‘Regulation of animal subjects research,’ The Regulatory Review
Oct. 9: ‘UC Health Conducts Clinical Trials for Regeneron Antibody Treatment Given to President Trump,’ CBS 4 TV (Denver, CO)
Oct. 9: ‘10,000 mink are dead in COVID-19 outbreaks at US fur farms after virus believed spread by humans,’ CNN
Oct. 9: ‘Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity,’ Proceedings of the National Academy of Sciences of the United States of America
Oct. 9: ‘REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters,’ Science
Oct. 9: ‘Horse plasma can be used to treat Covid-19 patients, says ICMR study,’ Hindustan Times
Oct. 9: ‘Scientists warn of human-to-wildlife COVID-19 transmission risk,’ UPI
Oct. 8: ‘Dual flu-Covid nasal spray vaccine to start trial in Hong Kong,’ Bloomberg
Oct. 8: ‘SARS-CoV-2 may be able to infect a significant number of mammals,’ Medical News Today
Oct. 8: ‘Winter will make the pandemic worse. Here’s what you need to know,’ MIT Technology Review
Oct. 8: ‘Antibody drugs are no cure but seem promising for COVID-19,’ The Associated Press
Oct. 8: ‘“Significant” Covid-19 drug breakthrough,’ University of St Andrews
Oct. 8: ‘Hundreds of mink die from coronavirus at Wisconsin farm,’ WISN ABC12 TV (Milwaukee, WI)
Oct. 7: ‘Domestic COVID-19 DNA vaccine is counting days for phase 1 trials Ege University has switched to animal experiments on COVID-19 DNA vaccine,’ Corona 24 News
Oct. 7: ‘Brookings lab develops COVID-19 vaccine for pets,’ Dakota News Now
Oct. 7: ‘Saying human trials aren’t enough, researchers call for comparison of COVID-19 vaccines in monkeys,’ Science
Oct. 7: ‘COVID-19: Nitric oxide shows promise as antiviral treatment,’ Medical News Today
Oct. 6: ‘COVID-19 ravages Utah mink farms. Utah’s State Veterinarian tells nearby humans not to worry,’ Daily Kos
Oct. 6: ‘Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines,’ Proceedings of the National Academy of Sciences of the United States of America
Oct. 6: ‘EU reviewing Pfizer-BioNTech COVID-19 vaccine in real time,’ Reuters
Oct. 6: ‘President Trump’s Covid cocktail therapy was tested in San Antonio,’ San Antonio Business Journal
Oct. 6: ‘Reliance Life Sciences joins hunt for COVID-19 vaccine,’ The Times of India
Oct. 6: ‘Vanderbilt researchers develop publicly available COVID-19 animal susceptibility prediction tool; suggests increased risk to horses,’ Vanderbilt
Oct. 6: ‘Face masks: what the data say,’ Nature journal
Oct. 6: ‘San Antonio lab clones COVID-19 in race for a cure,’ KENS TV (San Antonio, TX)
Oct. 5: ‘China Biotech Services (8037.HK) and National Institute for Viral Disease Control and Prevention (NIVDC) to develop genetically engineered recombinant vaccine for COVID-19,’ ACN Newswire
Oct. 5: ‘Pigs, horses and rabbits could all be at at risk of coronavirus, study shows,’ Daily Star
Oct. 5: ‘Could a common antioxidant enzyme help treat COVID-19?’ Medical News Today
Oct. 5: ‘Eli Lilly’s LY-CoV555 antibody shows potential as COVID-19 treatment,’ News Medical
Oct. 5: ‘FDA grant to study immune correlates for SARS-CoV-2,’ RT
Oct. 5: ‘Update: Here’s what is known about Trump’s COVID-19 treatment,’ Science
Oct. 5: ‘Dozens of mammals including pigs and horses could be susceptible to coronavirus, study shows,’ The Independent
Oct. 5: ’26 animals “regularly in contact with people may be susceptible to coronavirus,” study suggests,’ Yahoo
Oct. 5: ‘Could an Intranasal COVID-19 Vaccine Be More Efficient and Effective Than Traditional Approach?,’ BioSpace
Oct. 5: ‘Blood of the horseshoe crab may aid in coronavirus vaccine, but CT researchers worry about species,’ New Haven Register (New Haven, CT)
Oct. 4: ‘Mayo Clinic studying President Trump’s experimental treatment,’ KARE 11
Oct. 3: ‘Donald Trump, thank cats for remdesivir,’ Steve Dale Pet World
Oct. 2: ‘Trump hospitalized at Walter Reed after COVID-19 diagnosis,’ CNN
Oct. 2: ‘Regeneron stock surges 3.4% in after-hours trading after White House doctor revealed Trump is receiving its “antibody cocktail” to treat COVID-19,’ Daily Mail
Oct. 2: ‘Thousands of minks dead as COVID outbreak escalates on Utah farms,’ Kaiser Health News
Oct. 2: ‘Experimental antibody cocktail used by Trump following COVID-19 diagnosis was tested in San Antonio labs,’ KENS 5
Oct. 2: ‘Donald Trump should be better in a week after taking experimental drug, Regeneron CEO says,’ Newsweek
Oct. 2: ‘Denmark to cull up to one million mink due to risk of coronavirus contagion,’ Reuters
Oct. 2: ‘Trump treated with Westchester pharmaceutical’s promising experimental COVID breakthrough,’ Rockland/Westchester Journal News
Oct. 2: ‘Trump gets experimental drug aimed at curbing severe illness,’ The Associated Press
BREAKING NEWS: Oct. 2: ‘Trump flown to Walter Reed after COVID-19 diagnosis and getting an experimental Regeneron treatment,’ STAT News
President Trump’s experimental monoclonal antibody treatment, produced by Regeneron Pharmaceuticals, Inc. and in late-stage clinical testing, has proven effective in laboratory and animal tests.
Oct. 1: ‘LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection,’ bioRxiv
Oct. 1: ‘We will have trouble for another 6 months; miracle spray to COVID-19,’ Corona 24 News
Oct. 1: ‘How will we know if a coronavirus vaccine is safe?’ Spectrum News 1
Sept. 30: ‘Early data shows Regeneron’s COVID-19 antibody cocktail helps patients recover faster,’ BioSpace
Sept. 30: ‘Study: THC in marijuana could help avert fatal COVID-19 complications,’ FOX TV Stations
Sept. 30: ‘OSU’s COVID-19 testing lab moves to new home,’ KOKH
Sept. 30: ‘“Provocative results” boost hopes of antibody treatment for COVID-19,’ Science
Sept. 30: ‘These laboratory-made antibodies are a best bet for a coronavirus treatment, but there won’t be enough,’ The Washington Post
Sept. 29: ‘Cats could help researchers unlock a COVID-19 vaccine, research suggests,’ CTV News
Sept. 29: ‘Nasal spray could prevent COVID-19, new research shows,’ Healthcare Global
Sept. 29: ‘Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats,’ Proceedings of the National Academy of Sciences of the United States of America
Sept. 29: ‘Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults,’ The New England Journal of Medicine
Sept. 29: ‘Cats shed more than dogs. The coronavirus, not fur,’ The New York Times
Sept. 28: ‘Novel nasal spray reduces viral replication by up to 96%: according to COVID-19 challenge study,’ BioPharma-Reporter
Sept. 28: ‘J&J’s single-dose COVID-19 vaccine generates strong immune response, early data shows,’ BioSpace
Sept. 28: ‘Whither COVID-19 vaccines?’ Nature Biotechnology
Sept. 28: ‘Hamsters and ferrets clear low dose SARS-CoV-2 infection in 14 days,’ News Medical
Sept. 28: ‘Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study,’ PR Newswire
Sept. 28: ‘Pregnant and lactating women should not be excluded from COVID-19 drug, vaccine trials,’ STAT News
Sept. 28: ‘Cambodia’s beautiful gibbons could be vulnerable to COVID-19, study warns,’ VICE News
Sept. 27: ‘Bacteria-free method for making SARS-CoV-2 infectious clones,’ News Medical
Sept. 27: ‘Australian firm says its nasal spray reduced coronavirus growth in animal study,’ Reuters
Sept. 25: ‘The hunt for the “holy grail”: N.J. pharmaceutical companies look to develop lifesaving COVID-19 vaccine,’ Jersey’s Best
Sept. 25: ‘Study suggests eyeglasses may reduce risk of COVID infection,’ KGTV
Sept. 25: ‘China’s Clover says its coronavirus vaccine candidate showed promise in animal test,’ Reuters
Sept. 24: ‘Doctor who developed tetanus vaccine is now working for COVID-19 vaccine,’ Corona 24 News
Sept. 24: ‘Leiden corona vaccine seems to work: “so far only good news,”’ Corona 24 News
Sept. 24: ‘With a $4M federal grant, Lumen jumps into the COVID-19 treatment race,’ Endpoints News
Sept. 24: ‘Farm-to-plate study to investigate SARS-CoV-2 in beef production,’ Feedstuffs
Sept. 24: ‘T-cell-based vaccine effective against multiple influenza virus strains,’ Genetic Engineering & Biotechnology News
Sept. 24: ‘Dozens of COVID-19 vaccines are in development. Here are the ones to follow,’ National Geographic
Sept. 24: ‘Johnson & Johnson vaccine candidate to begin phase 3 of human trials,’ The Science Times
Sept. 23: ‘Avigan maker to seek virus treatment approval after trials,’ Agence France-Presse
Sept. 23: ‘Bharat Biotech inks licencing deal with Washington University School of Medicine for Covid intranasal vaccine,’ Hindustan Times
Sept. 23: ‘SARS-CoV-2 vaccines in development,’ Nature
Sept. 23: ‘J&J kicks off study of single-shot COVID-19 vaccine in 60,000 volunteers,’ Reuters
Sept. 23: ‘COVID vaccine update: Johnson & Johnson begins trials of one-shot drug,’ Tech Times
Sept. 23: ‘Stopping SARS-CoV-2 along the farm-to-plate supply chain,’ Texas A&M AgriLife
Sept. 23: ‘Australia’s just signed up for a shot at 9 COVID-19 vaccines. Here’s what to expect,’ The Conversation
Sept. 23: ‘Johnson & Johnson’s vaccine advances, sparking optimism in race,’ The New York Times
BREAKING NEWS: Sept. 23: ‘A single-shot coronavirus vaccine from Johnson & Johnson will be tested in 60,000 people,’ The Washington Post
Johnson & Johnson’s single-shot vaccine moved into the final stages of testing after research with monkeys.
“With a larger trial, it also increases the safety data set,” said Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. “Safety has been a lot in the public eye, and increasing the size of trials increases the safety data set, as well.”
BREAKING NEWS: Sept. 22: ‘Pfizer is on track to be first to find out if its Covid vaccine works,’ Bloomberg
“Pfizer’s trial was designed to evaluate its vaccine candidate ‘as fast as possible,’ said Amy Rose, a spokeswoman, in an email. The company has worked with government scientists to develop best practices for testing and based its schedule for interim analyses on the vaccine’s ‘strong profile’ in early human trials and animal tests, she said,” the report noted.
Sept. 22: ‘How and when will we know that a COVID-19 vaccine is safe and effective?’ The Conversation
Sept. 22: ‘The state of COVID antibody tests,’ The Corvallis Advocate
Sept. 22: ‘Finland to deploy coronavirus-sniffing dogs at Helsinki Airport,’ The Washington Post
Sept. 22: ‘COVID-19 vaccines could end up with bias built right in,’ WIRED
Sept. 21: ‘How the COVID-19 pandemic highlights the necessity of animal research,’ Current Biology
Sept. 21: ‘An ancient animal off the coast of SC holds a key element for coronavirus vaccine testing,’ Greenville News
Sept. 21: ‘Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years,’ Science
Sept. 21: ‘Explainer: How clinical trials test COVID-19 vaccines,’ The Conversation
Sept. 20: ‘Pets, vets and protocols: Animal attraction bringing out the best, and beast, in us,’ NNY360
Sept. 19: ‘Quarantine area for COVID-19 infected animals. It’s incredible what country made this decision!’ Corona 24 News
Sept. 18: ‘COVID-19 likely spreading from people to animals—and vice versa,’ CIDRAP News
Sept. 18: ‘Why misinformation about COVID-19’s origins keeps going viral,’ National Geographic
Sept. 18: ‘SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and shedding of infectious virus from both respiratory and gastrointestinal tracts,’ PLOS Pathogens
Sept. 18: ‘Scientists discover potential coronavirus remedy — at least, for mice and hamsters,’ The Associated Press
Sept. 17: ‘Study suggests substantial proportion of pet cats and dogs are infected with SARS-CoV-2 by their owners, due to presence of antibodies in their blood,’ European Society of Clinical Microbiology and Infectious Diseases
Sept. 17: ‘More pets may be getting COVID-19 than realized,’ HealthDay News
Sept. 17: ‘Animal data supports efficacy of baricitinib vs SARS-COV-2,’ News Medical
Sept. 17: ‘SARS-CoV-2 spike D614G mutant is more transmissible than other mutants,’ News Medical
Sept. 17: ‘Animals’ susceptibilty to coronavirus subject of U of I research,’ University of Idaho
Sept. 17: ‘“Substantial” portion of pets catch SARS-CoV-2, study finds,’ VIN News Service
Sept. 17: ‘The NIH launches a global hunt for animal-to-human diseases,’ WIRED
Sept. 16: ‘Pfizer says its Covid vaccine is just the first in a new wave of preventives,’ Barron’s
Sept. 16: ‘In possible major breakthrough, researchers develop drug that completely neutralizes COVID,’ CBSNew York
Sept. 16: ‘New COVID-19 Breakthrough at the University of Pittsburgh,’ Erie News Now
Sept. 16: ‘Applied DNA to initiate clinical trial of COVID-19 vaccine for cats,’ Reuters
Sept. 16: ‘More cats may be COVID-positive than thought, scientists suggest,’ Study Finds
Sept. 16: ‘Study hints antibody drug may cut COVID-19 hospitalizations,’ The Associated Press
BREAKING NEWS: Sept. 16: ‘An experimental drug protects COVID-19 patients, Eli Lilly claims,’ The New York Times
Eli Lilly’s monoclonal antibody treatment for COVID-19 reduced levels of the virus in pateints, the company said.
Sept. 16: ‘Vaxart can still be a major force in the COVID-19 vaccine landscape, says analyst,’ TipRanks
Sept. 15: ‘Researchers discover antibody molecule they say can prevent, treat COVID-19,’ Just The News
Sept. 15: ‘Drug that could treat and prevent COVID-19 licensed by new UPMC-backed company for worldwide development,’ KDKA
Sept. 15: ‘University Of Pittsburgh scientists discover biomolecule that may neutralize coronavirus,’ KDKA
Sept. 15: ‘UPMC doctors tout “breakthrough” COVID-19 drug which could prove valuable if vaccine fails,’ PennLive.com
Sept. 15: ‘You had COVID-19. Should you take the vaccine anyway? Scientists search for an answer,’ McClatchy DC
Sept. 15: ‘Breakthrough in potential drug to treat and prevent COVID-19,’ WHTM
Sept. 15: ‘Pitt, UPMC scientists discuss drug discovery that could treat, prevent COVID-19,’ WTAE-TV
Sept. 15: ‘Vaxart gets FDA nod for phase I study on coronavirus vaccine,’ Zachs
Sept. 14: ‘Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review,’ BMJ Open
Sept. 14: ‘University of Pittsburgh scientists discover antibody that “neutralizes” virus that causes COVID-19,’ Fox News
Sept. 14: ‘Vaxart announces FDA clearance of IND application for oral COVID-19 vaccine and provides update on COVID-19 program,’ Globe Newswire
Sept. 14: ‘Army COVID-19 vaccine may produce a side benefit: Cure for the common cold,’ McClatchy DC
Sept. 14: ‘Pitt/UPMC breakthrough could help treat, protect against COVID-19,’ Pittsburgh Business Times
Sept. 14: ‘“Trained Immunity” Offers Hope in Fight Against Coronavirus,’ Quanta Magazine
Sept. 14: ‘Covid vaccine developer to start clinical trial this month,’ San Francisco Business Times
Sept. 12: ‘Animal trials of coronavirus vaccine Covaxin have been successful, announces Bharat Biotech,’ News18
Sept. 12: ‘Bharat Biotech’s Covid vaccine generated “robust immune response” on animals,’ Healthworld.com
Sept. 12: ‘Animal study proved Covid vaccine’s efficacy: Bharat Biotech,’ The Times of India
Sept. 12: ‘Indian vaccine maker says Covaxin animal trials generate “robust immune response,”’ Xinhua News Agency
Sept. 11: ‘Animal study proved Covid vaccine’s efficacy: Bharat Biotech,’ Indo-Asian News Service
Sept. 11: ‘Inside Oxford’s vaccine saga: From wild hype to sobering reality,’ Politico Magazine
Sept. 11: ‘Cats saving the day, helping humans to deal with COVID-19,’ Steve Dale Pet World
Sept. 11: ‘Safety first: How to run a COVID-19 vaccine clinical trial,’ Wellcome
BREAKING NEWS: Sept. 10: ‘America is facing a monkey shortage as demand skyrockets for COVID-19 research, experts say,’ USA Today
American research is facing a critical primate shortage in the midst of important COVID-19 work.
Sept. 9: ‘One leading coronavirus vaccine might be ready next month,’ BGR
Sept. 9: ‘African green monkey helps battle against COVID-19,’ BioMedWire
Sept. 9: ‘Pfizer and BioNTech announce data from preclinical studies of mRNA-based vaccine candidate against COVID-19,’ Business Wire
Sept. 9: ‘Cats may be contracting COVID-19 at a higher rate than thought before: Study,’ CTV News
BREAKING NEWS: Sept. 9: ‘Pfizer touts nonhuman preclinical trial results for COVID-19 vaccine candidate,’ Drug Discovery & Development
“The data we have shared today include the characterization of our lead candidate BNT162b2, as well as key animal studies that were the basis for our clinical programs. They have enabled us to advance BNT162b2 into Phase 3 evaluation,” BioNTech founder & CEO Dr. Ugur Sahin said. “This is another development milestone for providing a safe and effective potential vaccine to the global community to help end this pandemic.”
Sept. 9: ‘Could your masks be a type of vaccine towards COVID-19?’ HealthDay
Sept. 9: ‘A leading coronavirus vaccine trial is on hold: Scientists react,’ Nature
Sept. 9: ‘The underdog coronavirus vaccines that the world will need if front runners stumble,’ Nature
Sept. 9: ‘Creating a COVID-19 vaccine,’ Your Fantastic Mind
Sept. 8: ‘The coronavirus is mutating — does it matter?’ Nature
Sept. 8: ‘It will take more than a vaccine to beat COVID-19,’ The New Yorker
Sept. 8: ‘Trio of medications showing early promise against coronavirus, UF Health researchers find,’ UF Health
Sept. 8: ‘Veterinary college partners with Humane Genomics Inc. on COVID-19 vaccine development,’ WLTZ
Sept. 7: ‘J&J’s lead COVID-19 vaccine candidate prevents severe disease in pre-clinical studies,’ HospiMedica International
Sept. 7: ‘When antibodies mislead: The quest for validation,’ Nature
Sept. 7: ‘Bold hopes for virus antibody tests still unfulfilled,’ The Associated Press
Sept. 7: ‘Can you get COVID-19 from your dog? Here’s what disease experts say,’ The Wall Street Journal
Sept. 5: ‘COVID-19 ends Dutch mink farming,’ The Economist
Sept. 4: ‘Johnson & Johnson’s COVID-19 vaccine prevents illness in hamsters,’ Financial Buzz
Sept. 4: ‘Johnson & Johnson Covid vax prevents severe clinical illness in hamsters,’ Telangana Today
Sept. 4: ‘Animals in the fight against COVID-19,’ Harvard University Blog
Sept. 4: ‘Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia,’ The Lancet
Sept. 4: ‘Tiffany Haddish discusses her positive coronavirus test with Dr. Anthony Fauci,’ Vulture
Sept. 3: ‘BIDMC-led research team reports vaccine protection against severe COVID-19-related pneumonia and death,’ Beth Israel Deaconess Medical Center
Sept. 3: ‘Johnson & Johnson says coronavirus vaccine prevents severe illness in hamsters,’ CNBC
BREAKING NEWS: Sept. 3: ‘Johnson & Johnson : Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies,’ MarketScreener.com
“In the pre-clinical study, researchers first immunized Syrian golden hamsters with a single injection of the Ad26-based SARS-CoV-2 vaccine, which induced neutralizing antibodies in all the vaccinated animals. Four weeks later, the animals were exposed to a high dose of SARS-CoV-2 virus,” the press release said. “These vaccinated animals lost less weight and had less virus in their lungs and other organs than unvaccinated control animals. Mortalities were absent in vaccinated animals. Moreover, the researchers found that neutralizing antibody responses were inversely correlated with weight loss and viral replication in the lung.”
Sept. 3: ‘Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters,’ Nature Medicine
Sept. 3: ‘COVID-19 vaccine study shows severe disease preventable in hamsters,’ OHSU
Sept. 3: ‘Leader of U.S. vaccine push says he’ll quit if politics trump science,’ Science
Sept. 2: ‘Do animals get C0VID 19? Can they pass it to us?’ The Daily Reporter
Sept. 1: ‘APG researchers, UPenn training dogs to detect asymptomatic coronavirus carriers; further testing coming,’ The Baltimore Sun
Sept. 1: ‘Women leading COVID-19 research at UC Davis: JoAnn Yee, manager of the Primate Assay Laboratory,’ The California Aggie
Sept. 1: ‘Who’s to blame for the pandemic?’ The New York Times
Sept. 1: ‘Past vaccine disasters show why rushing a coronavirus vaccine now would be “colossally stupid,”’ The East Bay Times
Sept. 1: ‘Research suggests coronavirus vaccine will likely require 2 shots to be effective,’ WTTG FOX 5
Sept. 1: ‘Drug Used For Cat Coronavirus Infections Fast-Tracked For Clinical Trial In Humans With Covid-19,’ Forbes.com
Aug. 31: ‘America Is Running Low on a Crucial Resource for COVID-19 Vaccines,’ The Atlantic
Aug. 31: ‘US ‘hit with monkey shortage for coronavirus trials’ as China hoards animals,’ The U.K. Daily Star
Aug. 31: ‘NIAID awards BioCryst new $44 million contract to advance development of Galidesivir,’ Marketwire
Aug. 31: ‘NIAID awards BioCryst new $44 million contract to advance development of Galidesivir,’ Marketwire
Aug. 31: ‘New federal certification streamlines OSU veterinary lab’s COVID-19 testing process,’ Oregon State University
Aug. 31: ‘There is hope: 16 innovations that could put an end to COVID,’ Home Health Choices
Aug. 31: ‘Cats point the way to potential COVID-19 remedies,’ Fierce Biotech
Aug. 29: ‘Gratifying progress in domestic COVID-19 study,’ Corona 24 News
Aug. 29: ‘California university scientists find hundreds of animal species potentially vulnerable to COVID-19,’ International Business Times
Aug. 29: ‘Drug used to treat coronavirus in cats may be effective for humans too: study,’ CTV News
Aug. 27: ‘Coronavirus tracker: Pfizer, BioNTech hit halfway mark on phase 3 enrollment; J&J plots phase 3 trials in Chile, Argentina and Peru,’ Fierce Pharma
Aug. 27: ‘Coronavirus vaccine tracker,’ The New York Times
Aug. 26: ‘Moderna’s COVID-19 vaccine may work better in the elderly than competitors,’ BioCentury
Aug. 26: ‘State, local public health veterinarians work long hours to protect the public,’ Journal of the American Veterinary Medical Association
Aug. 26: ‘COVID-19: Nasal vaccine shows promise in mouse study,’ Medical News Today
Aug. 26: ‘Moscow announces advanced trials for new COVID-19 vaccine,’ The Associated Press
Aug. 26: ‘Hydroxychloroquine does not inhibit SARS-CoV-2 infection in preclinical models,’ Wyss Institute
Aug. 25: ‘Alabama research into nasal spray vaccine for coronavirus posts promising results,’ AL.com
Aug. 25: ‘Animal testing: That is why there can be no quick exit,’ Archyde
Aug. 25: ‘More positive results from COVID-19 vaccine research at UAB,’ Birmingham Business Journal
Aug. 25: ‘Australian COVID-19 vaccine produces ZERO side effects in human trials and provides protection against the virus in animals while reducing symptoms,’ Daily Mail Australia
Aug. 25: ‘COVID-19’s impact on the animal kingdom—so far,’ National Geographic
BREAKING NEWS: Aug. 25: ‘Translate Bio, Sanofi COVID-19 vaccine candidate produces immune response in animal studies,’ Reuters
Translate Bio and Sanofi’s vaccine candidate produced positive results in animal studies.
Aug. 25: ‘Dr. Fauci tells veterinarians diseases from animals “a perpetual challenge,”’ San Bernardino American News
Aug. 25: ‘PharmAust (ASX:PAA) continues testing COVID-19 treatment,’ The Market Herald
Aug. 24: ‘Did pangolin trafficking cause the coronavirus pandemic?’ The New Yorker
Aug. 24: ‘Cuba surprises: Announces the start of trials of its vaccine against COVID. It’s called “Sovereign 01,”’ EFE
Aug. 24: ‘Pandemic threatens half-century of efforts to protect rare monkeys,’ National Geographic
Aug. 24: ‘China’s “insect” vaccine for COVID-19 approved for human testing,’ Pharmafile.com
Aug. 24: ‘Study of China “insect” vaccine for COVID-19 set to begin,’ Seeking Alpha
Aug. 24: ‘Urged on by scientists, NIH will study Gilead’s remdesivir-like compound against COVID-19,’ STAT News
Aug. 23: ‘Made-in-Canada COVID-19 vaccine effort slowed by manufacturing delay,’ CBC News
Aug. 23: ‘Doctors issue chilling warning over “rushed” coronavirus vaccine they say could have harmful side-effects – and reveal why government SHOULDN’T punish people who refuse the jab,’ Daily Mail Australia
Aug. 22: ‘China approves human testing for coronavirus vaccine grown in insect cells,’ Reuters
Aug. 21: ‘US FDA halts approval for plasma therapy to treat Covid: Report,’ Indo-Asian News Service
Aug. 21: ‘“Can pets spread coronavirus?” Dr. John Howe discusses pets and COVID-19,’ WGN
Aug. 20: ‘Houston health institutions enrolling COVID patients in rigorous plasma studies,’ Houston Chronicle
Aug. 20: ‘New SARS-CoV-2 vaccine effective in macaques,’ News Medical
Aug. 20: ‘Viruses have big impacts on ecology and evolution as well as human health,’ The Economist
Aug. 20: ‘Drug pitched to Trump for COVID-19 comes from a deadly plant,’ The New York Times
Aug. 20: ‘Yerkes genomics research will help predict COVID-19 disease severity, inform treatment decisions,’ Woodruff Health Sciences Center
Aug. 19: ‘U.S.-Swiss pact to triple supply of emerging COVID-19 treatment,’ Bloomberg
Aug. 19: ‘FDA emergency approval on hold for blood plasma to treat COVID-19,’ HealthDay News
Aug. 19: ‘Poisonous plant touted by MyPillow CEO is not a “miracle cure” for COVID-19,’ KHOU
Aug. 19: ‘FDA suspends COVID-19 emergency approval treatment,’ Newsmax
Aug. 19: ‘Turkey in talks with Germany, China, Russia on vaccine trials,’ Reuters
Aug. 19: ‘Will COVID-19 vaccines be safe for children and pregnant women? The data, so far, are lacking,’ STAT News
Aug. 19: ‘CUNY med school, TechnoVax report COVID-19 vaccine breakthrough,’ The City College of New York
Aug. 19: ‘Pets, livestock and wildlife can all catch coronavirus – does that make them dangerous?’ The Conversation
Aug. 19: ‘F.D.A.’s emergency approval of blood plasma is now on hold,’ The New York Times
Aug. 18: ‘COVID-19 hits U.S. mink farms after ripping through Europe,’ Science
Aug. 18: ‘WUSM St. Louis introduces VSV-SARS-CoV-2, a COVID-19 vaccine still in preclinical: Pushing for clinical trials,’ TrialSite News
Aug. 17: ‘White House focus on oleandrin treatment for coronavirus would be “nonsense,” experts say,’ CNN
Aug. 17: ‘Costa Rica readies horse antibodies for trials as an inexpensive COVID-19 therapy,’ Scientific American
Aug. 17: ‘Experimental Covid vaccine prevents pneumonia, yields high antibody levels in mice,’ Study Finds
Aug. 17: ‘Utah mink test positive for the virus that causes COVID-19 in humans,’ The Salt Lake Tribune
Aug. 17: ‘USDA confirms SARS-CoV-2 in mink in Utah,’ USDA Animal and Plant Health Inspection Service
Aug. 14: ‘Could dogs help in the detection of COVID-19? Studies suggest it’s possible,’ Graham Media Group
Aug. 14: ‘SA regulatory authorities won’t license Russian vaccine without access to evidence – prof Gray,’ Health24
Aug. 14: ‘DNA vaccine protection against SARS-CoV-2 in rhesus macaques,’ Science
Aug. 14: ‘What does the COVID-19 summer surge mean for your cats and dogs?’ Science
Aug. 14: ‘UC Davis research pivots to take on COVID-19,’ UC Davis Health
Aug. 14: ‘Making a COVID-19 vaccine is hard. Making one for kids is harder,’ WIRED
Aug. 14: ‘LMU vet students recognized by OIE for research on COVID-19 in animals,’ WVLT
Aug. 13: ‘Vaccine contrasts & massive volunteer mobilization: COVID-19 vaccine race, month 8,’ Absolutely Maybe
Aug. 13: ‘These are the top coronavirus vaccines to watch,’ The Washington Post
Aug. 13: ‘Vaxart positioned to further advance oral COVID-19 vaccine; analyst says “buy,”’ TipRanks
Aug. 12: ‘How AbbVie is bringing antiviral expertise to the COVID-19 battle,’ Abbvie.com
Aug. 12: ‘Russia claims they have a COVID-19 vaccine: Why you should be skeptical,’ Healthline
Aug. 12: ‘Could cat drugs treat humans with COVID-19?’ Live Science
Aug. 12: ‘Research looks at convalescent plasma use in COVID-19 mouse model,’ News Medical
Aug. 12: ‘1st U.S. dog with COVID-19 has died, and there’s a lot we still don’t know,’ NPR
Aug. 12: ‘Companies test antibody drugs to treat, prevent COVID-19,’ The Associated Press
Aug. 12: ‘The Middle East ramps up COVID-19 vaccine clinical trials and ongoing research & development,’ TrialSite News
Aug. 11: ‘Animal laboratories being used to process COVID-19 tests in an effort to speed up results,’ Healthline
Aug. 11: ‘Oral COVID-19 vaccine could activate both systemic and mucosal immunity for protection against coronavirus,’ HospiMedica International
Aug. 11: ‘Fauci “seriously doubts” the Russia vaccine is ready for widespread use,’ National Geographic
Aug. 11: ‘A singular view of COVID-19,’ Nature Biotechnology
Aug. 11: ‘North Carolina dog that died after “acute” illness tests positive for coronavirus,’ NBC News
Aug. 11: ‘VT opens new infectious disease center; job one: Coronavirus,’ Radio IQ
Aug. 11: ‘Antibody drugs could be one of the best weapons against COVID-19. But will they matter?’ STAT News
Aug. 11: ‘Inspired by llamas’ unique antibodies, scientists create a potent anti-coronavirus molecule,’ STAT News
Aug. 11: ‘DNA vaccine research is promising, NHRI says,’ Taipei Times
Aug. 11: ‘Scientists uneasy as Russia approves 1st coronavirus vaccine,’ The Associated Press
Aug. 11: ‘“This is all beyond stupid.” Experts worry about Russia’s rushed vaccine,’ The New York Times
Aug. 11 : ‘UCSF researchers develop nasal spray to fight coronavirus. It could be sold in stores,’ The Sacramento Bee
Aug. 11: ‘Russia unveils coronavirus vaccine “Sputnik V,” claiming breakthrough in global race before final testing complete,’ The Washington Post
Aug. 11: ‘N.C. dog dies after testing positive for virus that causes COVID-19 in humans,’ WBTV
Aug. 11: ‘XpressBio assists preeminent primate research center with coronavirus research Study,’ XpressBio
Aug. 10: ‘BIOQUAL announces publication in The New England Journal of Medicine of nonhuman primate preclinical viral challenge study of an mRNA vaccine against COVID-19 (mRNA-1273),’ Business Wire
Aug. 10: ‘How the COVID-19 pandemic highlights the necessity of animal research,’ Current Biology
Aug. 10: ‘Decoys could trick COVID-19, keep humans safe from infection,’ Live Science
Aug. 10: ‘BRIEF-Inovio says COVID-19 vaccine candidate to enter Phase 2/3 study in Sept – conf call,’ Reuters
Aug. 10: ‘Taiwan’s DNA-based COVID-19 vaccine passes animal testing hurdle,’ Taiwan News
Aug. 10: ‘Alpacas provide new hope for a COVID-19 cure,’ The Age and The Sydney Morning Herald
Aug. 10: ‘Coronavirus drug and treatment tracker,’ The New York Times
Aug. 9: ‘MRNA-1273 SARS-CoV-2 vaccine likely effective in nonhuman primates,’ 2 Minute Medicine
Aug. 8: ‘Japanese scientists turn to silkworms for COVID-19 vaccine,’ Nikkei
Aug. 7: ‘Opinion: Animal disease prevention: Critical to the nation’s public health,’ Agri-Pulse
Aug. 7: ‘Doctor’s note: Are vaccine efforts against COVID-19 succeeding?’ Al Jazeera
Aug. 7: ‘A pill that may lessen COVID-related lung damage. Miami will be first in U.S. to test it,’ Miami Herald
Aug. 7: ‘Why deforestation and extinctions make pandemics more likely,’ Nature
Aug. 7: ‘Seeds of hope in COVID-19 vaccine preliminary data,’ Nature Medicine
Aug. 6: ‘Texas A&M research project identifies first COVID-19 positive cats in Texas,’ KBTX
Aug. 6: ‘COVID-19 disrupts important research projects, shutters labs indefinitely,’ Newswise
Aug. 6: ‘Pets in a pandemic: How a Portland veterinarian continues to care for her furry clientele,’ Next Generation Radio
Aug. 6: ‘Pets are testing positive for coronavirus,’ Route Fifty
Aug. 6: ‘Vaccine data from Novavax,’ Science Translational Medicine
Aug. 6: ‘Bad news about those COVID-sniffing dogs,’ Slate
Aug. 6: ‘Texas A&M research project identifies first COVID-19 positive cats in Texas,’ Texas A&M College of Veterinary Medicine & Biomedical Sciences
Aug. 5: ‘Elderly, minority trial recruits vital to COVID-19 vaccine success: expert,’ Agence France-Presse
Aug. 5: ‘Warp Speed makes J&J COVID-19 vaccine program fifth above $1B,’ BioCentury
Aug. 5: ‘Malaysia studying COVID-19 vaccine for animal testing,’ CodeBlue
Aug. 5: ‘Made-in-Canada vaccine passes animal testing hurdle, seeks government funding,’ CTV News
Aug. 5: ‘Could labs that test livestock ease COVID testing backlog for people? Well … maybe,’ Kaiser Health News
Aug. 5: ‘NIH-Moderna investigational COVID-19 vaccine shows promise in mouse studies,’ National Institutes of Health
Aug. 5: ‘SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness,’ Nature
Aug. 5: ‘Zoonotic host diversity increases in human-dominated ecosystems,’ Nature
Aug. 5: ‘Immunology is where intuition goes to die,’ The Atlantic
Aug. 5: ‘Another voice: Animal research critical in making a COVID-19 vaccine,’ The Buffalo News
Aug. 4: ‘Regeneron’s COVID-19 antibody looks promising in animal test,’ Barron’s
Aug. 4: ‘Novavax COVID-19 vaccine potently immunogenic with room to lower dose,’ BioCentury
Aug. 4: ‘Inovio’s COVID-19 vaccine candidate shows promise in trials,’ Homeland Preparedness News
Aug. 4: ‘Giroir says labs that test livestock could ease the COVID testing backlog for people,’ PolitiFact
Aug. 4: ‘Designer antibodies could battle COVID-19 before vaccines arrive,’ Science
Aug. 4: ‘Regeneron’s monoclonal antibody cocktail in primates,’ Science
Aug. 4: ‘Gilead faces renewed pressure to pursue remdesivir-like compound to fight COVID-19,’ STAT News
Aug. 4: ‘Can dogs get coronavirus? Yes, a Louisiana dog just did. Here’s what pet owners should know,’ The Advocate
Aug. 4: ‘UT Austin in preclinical stages of developing powerful inhalable form of remdesivir for COVID-19 patients,’ TrialSite News
Aug. 4: ‘First canine with COVID-19 reported in Louisiana,’ WBRZ
Aug. 3: ‘University of Washington (UW Medicine) and HDT Bio – HDT-301,’ Genetic Engineering & Biotechnology News
Aug. 3: ‘Study: “Antibody cocktail” blocks coronavirus from taking hold,’ Newsmax
Aug. 3: ‘Regeneron says antibody cocktail prevents and treats COVID-19 in animals,’ Reuters
Aug. 2: ‘Can pets catch COVID-19? Hong Kong’s City University begins testing animals for coronavirus amid owners’ concerns,’ South China Morning Post
Aug. 2: ‘Scientists study coronavirus outbreaks among minks in Europe,’ The Associated Press
Aug. 2: ‘Russia sets mass vaccination for October after shortened trial,’ The New York Times
Aug. 1: ‘Indian billionaires bet big on head start in coronavirus vaccine race,’ The New York Times
July 31: ‘BIOQUAL announces publication in Nature of nonhuman primate preclinical viral challenge study of single-shot Ad26 vaccine protects against SARS-CoV-2,’ Business Wire
July 31: ‘INOVIO’s COVID-19 DNA vaccine becomes only vaccine to demonstrate long-term protection in monkeys 13 weeks from vaccination,’ HospiMedica International
July 31: ‘Large U.S. COVID-19 vaccine trials will exclude pregnant women for now,’ Reuters
July 31: ‘COVID-19 vaccine candidate creates “robust protection” from virus in primates,’ Study Finds
July 30: ‘Inovio coronavirus vaccine study shows months of immunity in primates, sending stock higher,’ Benzinga
BREAKING NEWS: July 30: ‘Single-shot COVID-19 vaccine protects non-human primates,’ Beth Israel Deaconess Medical Center
“This vaccine led to robust protection against SARS-CoV-2 in rhesus macaques and is now being evaluated in humans,” said Barouch.
July 30: ‘Nonhuman primate data link higher neutralizing titers to stronger COVID-19 protection,’ BioCentury
July 30: ‘J&J, beginning first human trial, aims for a 1-shot coronavirus vaccine,’ BioPharma Dive
July 30: ‘J&J vaccine protects monkeys from COVID with single shot,’ Bloomberg
July 30: ‘INOVIO’s COVID-19 DNA vax effective in NHP,’ Contract Pharma
July 30: ‘NIAID scientists report Moderna COVID-19 vaccine boosts immune responses in primate airways,’ Homeland Preparedness News
July 30: ‘Moderna’s COVID-19 vaccine successfully generates robust immune response and protection against SARS-CoV-2 in monkeys,’ HospiMedica International
July 30: ‘Getting a COVID-19 vaccine — quickly and safely,’ Knowable Magazine
July 30: ‘Johnson & Johnson COVID-19 vaccine effective in animal trials,’ Local 4 News
July 30: ‘Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates,’ MarketWatch
July 30: ‘ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques,’ Nature
July 30: ‘Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques,’ Nature
July 30: ‘Inovio stock surges after experimental COVID-19 vaccine shows long-term protection in animals,’ Philadelphia Business Journal
July 30: ‘Staten Island dog, first canine in the United States to test positive for coronavirus, dies: report,’ New York Daily News
July 30: ‘INOVIO’s COVID-19 DNA vaccine INO-4800 provides protection with memory immune responses in nonhuman primates challenged with SARS-CoV-2 virus,’ PR Newswire
July 30: ‘Inovio vaccine candidate shows promise in non-human study,’ Reuters
July 30: ‘Johnson & Johnson starts human study of COVID-19 vaccine after promising monkey data,’ Reuters
July 30: ‘Coronavirus challenges in primates, compared,’ Science Translational Medicine
July 30: ‘“A huge experiment”: How the world made so much progress on a COVID-19 vaccine so fast,’ STAT News
July 30: ‘Moderna COVID-19 vaccine rapidly clears virus in lungs, noses of monkeys: Study,’ The Epoch Times
BREAKING NEWS: July 30: ‘Johnson & Johnson’s coronavirus vaccine protects monkeys, study finds,’ The New York Times
Johnson & Johnson’s experimental coronavirus vaccine protected monkeys. “It’s a very reassuring level of protection we saw,” said Dr. Dan Barouch.
July 29: ‘Moderna and NIAID publish positive COVID-19 vaccine data in monkeys,’ BioSpace
July 29: ‘Moderna says cororavirus vaccine shows promise in monkeys,’ CBS
July 29: ‘Moderna’s mysterious coronavirus vaccine delivery system,’ Forbes
July 29: ‘COVID-19 vaccine candidate provides protection in animal challenge study,’ MPR
July 29: ‘Exclusive: Buddy, first dog to test positive for COVID-19 in the U.S., has died,’ National Geographic
July 29: ‘Can household pets transmit coronavirus? Experts say risk is low,’ NBC
July 29: ‘Good news of coronavirus vaccine from Ankara,’ Star
July 29: ‘The next coronavirus may already be circulating in bats, study suggests,’ The Philadelphia Inquirer
July 29: ‘Heat Biologics: COVID-19 vaccine candidate shows promise in animal testing,’ Triangle Business Journal
July 28: ‘Nascent Biotech announces collaboration with Syracuse University – advancing COVID-19 research,’ Accesswire
July 28: ‘Face masks may make COVID-19 less severe,’ HealthDay News
July 28: ‘Survivors’ COVID antibodies may provide a powerful gift,’ HealthDay News
July 28: ‘Experimental COVID-19 vaccine protects higher and decrease airways in nonhuman primates,’ Home Health Choices
July 28: ‘Monkey data support Moderna COVID-19 vaccine,’ MedPage Today
July 28: ‘Experimental COVID-19 vaccine protects upper and lower airways in nonhuman primates,’ National Institute of Allergy and Infectious Diseases
July 28: ‘Animal models paved the way for Phase III testing of the COVID-19 vaccine,’ Speaking of Research
July 28: ‘Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates,’ The New England Journal of Medicine
BREAKING NEWS: July 28: ‘Moderna vaccine test in monkeys shows promise,’ The New York Times
“The virus was cleared very rapidly in the vaccinated animals,” said Dr. Barney S. Graham.
July 27: ‘COVID-19 can affect pets,’ AgriLife Today
July 27: ‘Cat becomes first animal in UK to test positive for COVID-19,’ CNN
July 27: ‘Lab-created virus can help COVID-19 research, developers say,’ HealthDay News
July 27: ‘Large-scale study Moderna COVID-19 vaccine to be fully enrolled in 4-6 weeks – CEO,’ Seeking Alpha
July 27: ‘MIT develops machine learning model to quicken release of COVID-19 vaccine,’ TechRepublic
July 27: ‘Yuhan-AbClon’s COVID-19 antibody therapy revs up for trials,’ The Korea Herald
July 27: ‘Research boosts evidence of masks’ utility, some experts say,’ The New York Times
July 27: ‘How a K-State research lab is fighting back against COVID-19,’ The Wichita Eagle
July 27: ‘RVC joins coronavirus research collaboration,’ Vet Times
July 27: ‘Local research center in race for COVID-19 vaccine,’ WOAI-TV
July 26: ‘We asked 3 Texas doctors: Will you get the first COVID-19 vaccine that becomes available?’ The Dallas Morning News
July 26: ‘Risk, uncertainty and fear of failure: Why scientists aren’t celebrating a coronavirus vaccine yet,’ The Telegraph
July 24: ‘CEL-SCI announces early results with COVID-19 LEAPS vaccine/treatment,’ Business Wire
July 24: ‘Another mRNA-based vaccine candidate protects animals against SARS-CoV-2,’ Cell Press
July 24: ‘Cheap generics might treat COVID-19, but obstacles abound,’ Medscape Medical News
July 24: ‘Gennova Biopharma’s vaccine candidate to undergo clinical trial before 2020 end,’ Mint
July 24: ‘Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing,’ Nature
July 24: ‘Department of Biotechnology provides seed funding for Gennova Biopharmaceuticals Ltd.’s novel mRNA based COVID-19 vaccine candidate-HGCO19,’ Press Information Bureau Delhi
July 24: ‘Chinese COVID-19 vaccine candidate shows promise in animal tests,’ Reuters
July 24: ‘Trump “owes us an apology.” Chinese scientist at the center of COVID-19 origin theories speaks out,’ Science
July 23: ‘Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy,’ bioRxiv
July 23: ‘German sniffer dogs show promise at detecting coronavirus,’ DW
July 23: ‘Can an animal vaccine developer be the one to tame COVID-19? MBF Therapeutics places its bet,’ Philadelphia Business Journal
July 23: ‘The long game of coronavirus research,’ The New Yorker
July 23: ‘New drugs developed by Australian researchers may help treat COVID-19 triggered blood clotting,’ Xinhua News Agency
July 22: ‘Novavax analyst “encouraged” by preclinical data for coronavirus vaccine candidate,’ Benzinga
July 22: ‘Neutralizing antibodies isolated from COVID-19 patients may suppress virus,’ Columbia University Irving Medical Center
July 22: ‘Hydroxychloroquine use against SARS-CoV-2 infection in nonhuman primates,’ Nature
July 22: ‘The hunt for the origins of SARS-CoV-2 will look beyond China,’ The Economist
July 21: ‘Next-gen vaccine from UW researchers shows promise in fighting COVID-19,’ GeekWire
July 21: ‘Coronavirus vaccines get a biotech boost,’ Nature
July 21: ‘Cautious optimism: On race for vaccines gather pace,’ The Hindu
July 20: ‘Academic labs are opening back up. Still, research isn’t exactly back to normal,’ Association of American Medical Colleges
July 20: ‘Coronavirus vaccine from Oxford and AstraZeneca shows positive response in early trial,’ CNBC
July 20: ‘Replicating RNA vaccine rebuffs COVID-19,’ DD News
July 20: ‘UW Medicine announces promising coronavirus vaccine prospect,’ KIRO 7 News
July 20: ‘Useful flexibilities for animal care and use programs to comply with the PHS policy during the COVID-19 pandemic,’ Open Mike
July 20: ‘Penn Vet seeking human help for canine research,’ Penn Vet
July 20: ‘Studies provide glimpse at efficacy of COVID-19 vaccines from Oxford-AstraZeneca and CanSino,’ STAT News
July 20: ‘Why vaccines are less effective in the elderly, and what it means for COVID-19,’ The Conversation
July 20: ‘Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial,’ The Lancet
July 20: ‘COVID-19 vaccine has hefty response in nonhuman primates,’ UW Medicine
July 20: ‘Lab-made virus mimics COVID-19 virus,’ Washington University School of Medicine in St. Louis
July 18: ‘COVID virus detected in S.C. dog after owner tested positive,’ The Associated Press
July 17: ‘From farmed mink to your pet cat, here’s what we know about coronavirus and animals,’ CNN
July 17: ‘The vaccine race,’ Frontline
July 17: ‘Inside Johnson & Johnson’s nonstop hunt for a coronavirus vaccine,’ The New York Times
July 17: ‘Vaxart’s soars YTD on robust coronavirus vaccine progress,’ Zachs
July 16: ‘J&J, on the cusp of starting coronavirus vaccine trials, sets high bar for success,’ BioPharma Dive
July 16: ‘A shepherd mix is the first dog in South Carolina to test positive for the coronavirus,’ The State
July 15: ‘Covid vaccine front-runner is months ahead of her competition,’ Bloomberg Businessweek
July 15: ‘COVID-19 vaccines are on the fast-track to approval. How will we know they’re safe?’ Live Science
July 15: ‘Potently neutralizing and protective human antibodies against SARS-CoV-2,’ Nature
July 14: ‘Virus vaccine candidate starts human tests,’ Australian Associated Press
July 14: ‘New molecule attacks COVID-19 on two fronts,’ Presse Canadienne
July 14: ‘Can Fluffy or Fido get COVID-19? Will they give it to me?’ Reform Austin News
July 14: ‘The pandemic virus is slowly mutating. But is it getting more dangerous?’ Science
July 14: ‘First data for Moderna COVID-19 vaccine show it spurs an immune response,’ STAT News
July 14: ‘Danish scientists announce “promising” COVID-19 vaccine tests,’ The Local
July 14: ‘Could llama antibodies be the key to a coronavirus treatment?’ The World
July 14: ‘KU Leuven breakthrough as modified yellow fever virus destroys COVID-19 in preclinical animal research: Clinical trials next,’ TrialSite News
July 13: ‘Qld COVID-19 human vaccine trials to start,’ Australian Associated Press
“There is no way the research team would be able to progress from animals to humans without a complete guarantee of safety and they would likely have a confidence in its effectiveness,” professor Robert Booy said.
July 13: ‘Vaccine ready “next year,”’ Bangkok Post
Vaccinated monkeys had COVID-19 antibodies.
July 13: ‘Second virus wave fears create growing demand for testing, treatments and vaccine candidates,’ PR Newswire
“At the forefront of the COVID-19 vaccine initiative is clinical-stage biotechnology company Vaxart, Inc. (NASDAQ:VXRT). The company, which is developing an oral COVID-19 vaccine, has been selected to participate in a nonhuman primate (NHP) challenge study that is being organized and funded by Operation Warp Speed, the Trump administration’s vaccine-acceleration program aimed to provide substantial quantities of a safe, effective vaccine for Americans by January 2021,” the press release said.
July 12: ‘Thailand to begin its COVID-19 vaccine human trials in September,’ Bloomberg
“We hope that the vaccine could generate neutralizing antibodies in humans seen in monkeys and mice,” Kiat Ruxrungtham, head researcher at Chulalongkorn University’s Center of Excellence in Vaccine Research and Development, said at a briefing Sunday.
July 11: ‘University of Minnesota leads work group on infectious dose of COVID-19,’ Star Tribune
“Scientists don’t yet know the infectious dose of the virus that causes COVID-19, but data from animal studies and evidence from other viruses could provide important clues, said Michael Osterholm, director of the U’s Center for Infectious Disease Research and Policy,” the article noted.
July 11: ‘Everything you need to know about Vaxart and its potential coronavirus vaccine,’ The Motley Fool
“This will be the second immunity study in animal models for the company’s COVID-19 vaccine; the first study reported favorable results in April, likely sparking the government’s interest,” the article said.
July 10: ‘Dog in Texas confirmed COVID-19 positive,’ Forbes
July 10: ‘Scientists call for pandemic investigations to focus on wildlife trade,’ Nature
July 10: ‘Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,’ Nature Medicine
July 10: ‘New data shows Gilead’s remdesivir “potently inhibited” SARS-CoV-2 in human lung cell cultures,’ Pharmafile.com
Research showed positive results in mice and human lung cell cultures.
July 10: ‘Fujifilm’s Avigan inconclusive in COVID-19 patients in Japan trial,’ Reuters
“Concerns remain about the drug as it has been shown to cause birth defects in animal studies,” the report noted.
July 10: ‘A WHO-led mission may investigate the pandemic’s origin. Here are the key questions to ask,’ Science
“The two-person team from the World Health Organization (WHO) traveling to China today to address the origin of the COVID-19 pandemic is unlikely to come home with answers. Rather, the duo—an epidemiologist and an animal health expert whose names have not been released—will discuss with Chinese officials the scope of a larger international mission later, according to a WHO statement,” the article said.
July 9: ‘Novavax receives highest funding to develop COVID-19 vaccine,’ ABC News
“When asked about the effectiveness of the vaccine, [Novavax CEO Stanley] Erck said early animal studies are promising,” the article noted.
July 9: ‘AIM ImmunoTech signs clinical trial agreement with Roswell Park Comprehensive Cancer Center supporting Phase 1/2 clinical trial of Ampligen combined with interferon alfa-2b in COVID-19 patients with cancer,’ Accesswire
“In earlier SARS-CoV-1 studies in mouse models, Ampligen demonstrated a protective effect,” the press release said.
July 9: ‘How the world could monitor for potential pandemic viruses,’ Axios
“Zoonotic diseases, or those that originated in animal hosts and transferred to humans, tend to be the ones that lead to pandemics. COVID-19, MERS, Ebola, bird flu and the West Nile virus are just some that have had devastating results,” the outlet reported.
July 9: ‘TAHC: North Texas family’s pet dog tests positive for virus that causes COVID-19,’ CBS19
July 9: ‘Pigs and chickens not susceptible to SARS-CoV-2,’ News Medical
July 9: ‘Tarrant County dog is first in Texas to test positive for virus that causes COVID-19,’ The Dallas Morning News
July 9: ‘These scientists raced to find a COVID-19 drug. Then the virus found them,’ The New York Times
“Regeneron has built its business on what Dr. Schleifer, one of the company’s founders, calls its ‘magical mice’ — animals that have been genetically engineered to have human immune systems. The mice are infected with harmless viruses that trigger the animals to produce human antibodies,” the article said.
July 9: ‘New study supports remdesivir as COVID-19 treatment,’ Vanderbilt University Medical Center
“All of the results with remdesivir have been very encouraging, even more so than we would have hoped, but it is still investigational, so it was important to directly demonstrate its activity against SARS-CoV-2 in the lab and in an animal model of disease,” VUMC’s Andrea Pruijssers said.
July 9: ‘Tarrant County dog infected with virus that causes COVID-19, state animal health officials say,’ WFAA
July 8: ‘Safety and tolerability of anti-coronavirus drug candidates observed in an animal model further advances NanoViricides’ SARS-CoV-2 therapeutics program,’ Accesswire
July 8: ‘Voltron Therapeutics, Inc. initiates animal testing of self-assembling vaccine in fight against COVID-19,’ Globe Newswire
July 8: ‘Can boosting interferons, the body’s frontline virus fighters, beat COVID-19?’ Science
Different studies of interferons for treating COVID-19 patients involve ferrets and mice and show that interferons may help fight off COVID-19.
July 7: ‘Novavax gets another boost with $1.6B contract from Operation Warp Speed,’ BioCentury
“At BIO’s annual meeting in June, Novavax reported nonhuman primate data showing NVX-CoV2373 elicited SARS-CoV-2 neutralizing titers in the 10,000 range, the highest levels disclosed thus far in monkey studies (see ‘Comparing Neutralizing Titers‘),” the report said.
July 7: ‘Novavax wins $1.6b in “Warp Speed” funding; plans first 100m doses of COVID-19 vaccine,’ Genetic Engineering & Biotechnology News
“Earlier this month, Vaxart and INOVIO announced their vaccine candidates were selected for a nonhuman primate (NHP) challenge study organized and funded by Operation Warp Speed,” the article said.
July 7: ‘US government awards Novavax $1.6 billion for coronavirus vaccine,’ Reuters
“‘… I don’t think we’re behind because of our data,’ [Novavax CEO Stanley] Erck said, referring to animal data showing a strong immune response and high levels of virus-killing antibodies,” the article said.
July 7: ‘US signs $450 million contract with Regeneron for COVID-19 therapy,’ Reuters
July 6: ‘Daewoong to stage clinical trials of COVID-19 treatment using stem cells,’ Aju Business Daily
“Daewoong Pharmaceutical, a major bioengineering company in South Korea, will carry out the first phase of clinical trials in Indonesia for COVID-19 respiratory symptom treatment using mesenchymal stem cells after drug efficacy tests using animal models have identified anti-inflammatory and antiviral effects,” the article said.
July 6: ‘Coronavirus: Fear over rise in animal-to-human diseases,’ BBC News
July 6: ‘Report finds rising trend of viruses jumping from animal hosts to humans,’ Deutsche Presse-Agentur GmbH
July 6: ‘Cannabis may reduce deadly COVID-19 lung inflammation: Researchers explain why,’ Forbes
“In an animal study on asthma, CBD was able to reduce production of proinflammatory cytokine production, actually reducing airway inflammation. In the same study CBD also reduced pulmonary fibrosis – a condition where lung tissue becomes damaged and scarred, thickening lung tissue and making breathing more difficult,” the article said. “This is important, because COVID-19 can also leave patients with serious pulmonary fibrosis.”
July 6: ‘Sorrento Therapeutics – T-VIVA-19,’ Genetic Engineering & Biotechnology News
“Sorrento said July 1 that it published a preprint study in bioRxiv reporting initial preclinical results showing that immunization with T-VIVA-19 via injection into either the vein or the thigh muscle of a mouse induced antibodies against the SARS-CoV-2 protein in all mice within the first week of administration,” the article said.
July 6: ‘Double coronavirus antibody cocktail launches Phase 3 study,’ Precision Vaccinations
“According to the Company, Regeneron’s scientists evaluated fully-human antibodies produced by the company’s proprietary VelocImmune® mice, which have been genetically-modified to have a human immune system, as well as antibodies isolated from humans who have recovered from COVID-19,” the post said.
July 6: ‘Vaxart: A speculative buy for its oral COVID-19 vaccine,’ Seeking Alpha
Vaxart announced that “its oral COVID-19 vaccine has been selected to participate in a nonhuman primate (NHP) challenge study, organized and funded by Operation Warp Speed.”
July 6: ‘New UN report outlines ways to curb growing spread of animal-to-human diseases,’ UN News
July 5: ‘Pets, vets, vaccines and the pandemic: Animal and human health entwined more than ever in COVID times,’ Capital Current
July 4: ‘Covaxin safety has already been well-established from animal tests: Bharat Biotech MD,’ The Financial Express
July 4: ‘Researchers launch large trials of COVID-19 candidate vaccines,’ VOA Learning English
“Animal research suggests COVID-19 vaccines could prevent serious disease but may not completely block infection. One study showed vaccinated animals avoided being infected with pneumonia but had some virus left in their noses and throats,” the article noted.
July 3: ‘Testing tuberculosis vaccine combos for COVID-19,’ Home Health Choices
“Our on-going studies will determine how long the immune response lasts after vaccination in animal models. This is important information for future human testing of our vaccine,” Centenary Institute analysis scientist Claudio Counoupas said.
July 3: ‘Bharat Biotech has passed mandated protocols, animal testing and is now in clinical development of Covid vaccine, Dr Krishna Ella tells Firstpost,’ Firstpost
July 3: ‘Six months of coronavirus: The mysteries scientists are still racing to solve,’ Nature
“But there are already clues in data from animal studies and early-stage human trials, mainly testing safety. Multiple teams have conducted ‘challenge trials’ in which animals given a candidate vaccine are intentionally exposed to SARS-CoV-2 to see whether the jab can prevent infection,” the article noted.
July 3: ‘Inside the race to develop a safe COVID-19 vaccine,’ Popular Science
“A new vaccine candidate must first be tested in animals before undergoing three phases of clinical trials in people,” the article said.
July 3: ‘Coronavirus vaccine: India’s second COVID-19 vaccine produced by Zydus Cadila cleared for human trials,’ The Times of India
“The company has submitted data to DCGI based on animal trial, they conducted. Animals like- mice, rabbits, guinea pigs, rats were used and these animals developed antibodies against the virus,” mentioned a report.
July 3: ‘Biotech ETFs to gain as coronavirus vaccine hopes strengthen,’ Zachs
“Going on, Vaxart, Inc.’s (VXRT) oral COVID-19 vaccine candidate has been picked up for investigation in a nonhuman primate challenge study,” the post said.
July 2: ‘Horseshoe crab blood is key to making a COVID-19 vaccine—but the ecosystem may suffer,’ National Geographic
July 2: ‘Novavax SARS-CoV-2 vaccine candidate shows promise in animal models,’ News Medical
July 2: ‘HBCU scientist working on COVID-19 antiviral,’ The American South
“Dr. Donald Alcendor, an associate professor of microbiology and immunology at Meharry Medical College, began working on the COVID-19 antiviral in April and anticipates it is four to six weeks away from animal toxicity testing,” the report said.
July 2: ‘UH professor working on COVID-19 vaccine,’ The Daily Cougar
“We have already completed the first round of preclinical animal testing and the results were quite encouraging,” University of Houston biology and biochemistry professor Zhang said. “I think there is no doubt that more research is needed for any vaccine development.”
July 1: ‘How lab animals have fared in the coronavirus crisis,’ DW
July 1: ‘The essential role of animal studies in expediating medical research to battle the COVID-19 pandemic,’ Fox Rothschild LLP
July 1: ‘Anti-viral and anti-inflammatory response: GoldenBiotech’s antroquinonol receives FDA approval on COVID-19 Phase 2 trial in USA,’ PR Newswire
“Antroquinonol was found to reduce viral nucleic acid replication and viral protein synthesis in both cell and animal experiments,” the press release said.
July 1: ‘Georgia dog tests positive for virus that causes COVID-19,’ The Atlanta Journal-Constitution
July 1: ‘Tulane receives $1 million from alum to fight coronavirus,’ The Times-Picayune | The New Orleans Advocate
“The Tulane National Research Primate Center, home to several thousand monkeys and a 40,000-square foot lab, received coronavirus samples in February to study how the virus spreads and might be treated,” the article said.
June 30: ‘Inovio COVID-19 vaccine data highlight questions about antibody versus T cell responses,’ BioCentury
“Inovio … said INO-4800 provided ‘full protection’ from SARS-CoV-2 replication in the lungs of mice,” the article said.
June 30: ‘Fauci says “there is no guarantee” for a safe COVID-19 vaccine, but he’s “cautiously optimistic,”’ CNN
“It’s extremely important to have safe and effective vaccines available for everyone in this country,” Fauci said in opening remarks before a Senate committee on June 30. He emphasized that researchers have made significant headway on experimental vaccines and therapies for COVID-19 thanks to preclinical vaccine and therapy trials with animal models.
June 30: ‘How will COVID-19 transform veterinary practice?’ DVM 360
June 30: ‘INOVIO reports positive interim Phase I data for COVID-19 DNA vaccine, joins “Warp Speed” primate study,’ Genetic Engineering & Biotechnology News
June 30: ‘“Going to be very disturbing”: Fauci warns coronavirus cases could reach 100K a day,’ NPR
“But we are cautiously optimistic, looking at animal data and the early preliminary data, that we will at least know the extent of efficacy sometime in the winter and early part of next year. … Hopefully, there will be doses available by the beginning of next year,” he said.
June 30: ‘Coronavirus vaccine candidate found 94% effective,’ Precision Vaccinations
“In addition to positive interim Phase 1 data, INO-4800 has been shown to protect mice in SARS-CoV-2 viral challenge studies, where vaccination with INO-4800 prevented viral replication in the lungs of animals challenged with SARS-CoV-2,” the article said.
June 30: ‘INOVIO announces positive interim Phase 1 data for INO-4800 vaccine for COVID-19,’ PR Newswire
“In addition to positive interim Phase 1 data, INO-4800 has been shown to protect mice in SARS-CoV-2 viral challenge studies, where vaccination with INO-4800 prevented viral replication in the lungs of animals challenged with SARS-CoV-2,” the press release said.
June 30: ‘Health officials face questions on virus vaccine,’ The Associated Press
Dr. Anthony Fauci testified during a Senate committee hearing and mentioned animal data.
June 30: ‘Test designed to detect equine disease shows promise for COVID-19,’ The Horse
June 30: ‘Inovio Pharmaceuticals vaccine ‘deemed safe’ in testing,’ TheStreet
“In addition, Inovio said that in a preclinical animal study, INO-4800 provided full protection against coronavirus replication in the lungs in mice that were infected with the virus,” the article said.
June 30: ‘COVID-19 lockdowns are a unique chance to study human-wildlife interactions, researchers say,’ The World
June 29: ‘Auburn College of Veterinary Medicine partners with Humane Genomics Inc. on COVID-19 vaccine development,’ Auburn University College of Veterinary Medicine
June 29: ‘India’s first COVID-19 vaccine candidate COVAXIN gets approval for human trials,’ Business Today
“Those within the industry say the company seems to have achieved vaccine stabilisation and completion of animal studies in record time considering that it was only on May 9, 2020 that the ICMR announced collaboration with Bharat Biotech ‘to develop a fully indigenous vaccine for COVID-19 using the virus strain isolated at ICMR’s National Institute of Virology (NIV), Pune,'” the article said.
June 29: ‘Canadian-made COVID-19 vaccine ready to start human trials soon,’ CTV News
“In earlier animal testing of the vaccine, which is produced in tobacco plants, mice began producing a positive antibody response within 10 days of receiving a single dose, researchers said in May,” the report noted.
June 29: ‘Vaxart oral COVID-19 vaccine joins Trump’s “Warp Speed,” ramps up manufacturing capacity,’ Genetic Engineering & Biotechnology News
“On April 30, Vaxart disclosed that it obtained positive preclinical results for its COVID-19 vaccine candidates, with ‘several’ of the candidates generating immune responses in all tested animals after a single dose,” the report said.
June 29: ‘Researchers looking for to grasp the connection between SARS-CoV-2 and a lethal immune system malfunction,’ Home Health Choices
“Between the preclinical data from animal models and the retrospective data from humans, we felt there was good rationale to test this concept with COVID-19,” said Chetan Bettegowda, a professor of neurosurgery at the Johns Hopkins School of Medicine.
June 29: ‘A race to determine what drives COVID-19 severity,’ Nature
June 29: ‘Swine flu strain with human pandemic potential increasingly found in pigs in China,’ Science
June 29: ‘How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective,’ The Catalyst
“Evaluation of vaccine safety begins in the earliest phases of research, with preclinical trials involving animal and human cells or tissue systems. In this phase, scientists examine whether vaccine candidates produce the outcome they expect, as well as look for any signs of negative reactions,” the blog post said.
June 29: ‘Coronavirus (COVID-19) vaccine status check: Oxford vaccine most advanced, says WHO; Sanofi accelerates trials,’ The Indian Express
“The Chulalongkorn project employs new mRNA vaccine technology and the team expects final results from the animal-testing stage in the next two weeks,” the article said.
June 28: ‘Summer may decide fate of leading shots in vaccine race,’ The Associated Press
“Animal research suggests COVID-19 vaccines could prevent serious disease but may not completely block infection. One study that dripped the coronavirus into monkeys showed vaccinated animals avoided pneumonia but had some virus lurking in their noses and throats,” the report said.
June 28: ‘US company with Israeli roots to test COVID-19 vaccine on humans by August,’ The Jerusalem Post
The company had successful trials with mice, rats, rabbits and pigs.
June 27: ‘Colorado State researchers scaling up production of potential COVID-19 vaccine,’ The Denver Post
“A possible vaccine for the new coronavirus has shown good enough results in animals to attract federal money to take it to the next level, but the Colorado State University researchers involved caution that it has many hurdles to clear before going to the public. CSU’s labs have produced a small amount of a vaccine and tested it on hamsters, said Ray Goodrich, executive director of the university’s Infectious Disease Research Center,” the article said. “The hamsters have formed an immune defense and don’t get sick if they’re exposed to the virus, but not everything that looks promising in small animals works as well in humans.”
June 27: ‘What’s special about Tonix Pharma and Southern Research’s COVID-19 vaccine candidate?’ The Pharma Letter
“The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix’ TNX-1800, which is a live replicating virus vaccine designed to protect against COVID-19. The data will support the interpretation of animal trial results with TNX-1800, which are expected in the fourth quarter of 2020 and subsequent human trials,” the post said.
June 27: ‘SDSU and UCSD developing low-cost, easy-to-make ventilators for COVID-19 patients,’ The San Diego Union-Tribune
SDSU Assistant Professor of Mechanical Engineering Kevin “Wood has been in touch with physicians in Tijuana and officials at COFEPRIS (Mexico’s equivalent of the FDA) about getting the device approved for use in Mexico. That will likely involve additional animal experiments, he says,” the article said.
June 26: ‘Local virus jab shows promise in animal tests,’ Bangkok Post
June 26: ‘Vaxart’s COVID-19 vaccine candidate tapped for Operation Warp Speed primate study,’ BioSpace
June 26: ‘U of O scientist seeking edible vaccine for COVID-19,’ CBC News
University of Ottawa plant biologist Allyson “MacLean’s work will be tested on mice in collaboration with John Bell of the Ottawa Health Research Institute,” the post said.
June 26: ‘Deadly animal diseases can jump to humans. Is vaccinating wildlife the answer?’ Discover Magazine
June 26: ‘Vaxart’s COVID-19 vaccine selected for the US government’s Operation Warp Speed,’ Globe Newswire
The company’s vaccine is in a nonhuman primate study.
June 26: ‘Animal research in pandemic response efforts,’ Laboratory Animal Science Professional
Click here to find the article on pages 18-20 and use the zoom button to enlarge the text. The article is available at this link for AALAS members.
June 26: ‘A little-known biotech working on a COVID-19 vaccine has surged 304% in 2 days — and it just said it was picked for the US government’s Operation Warp Speed program (VXRT),’ Markets Insider
“The firm said that its oral COVID-19 vaccine candidate would be involved in a nonhuman primate challenge study and that it was ‘the only oral vaccine being evaluated’ in the program,” the article said.
June 26: ‘COVID-19: Could gut bacteria be involved?’ Medical News Today
“Further to this, [researchers] explain that in mice, ‘removal of certain gut bacteria by antibiotic[s] leads to increased susceptibility to influenza virus infection in [the] lungs,’” the article said.
June 26: ‘Researchers continue progress on Colorado COVID-19 vaccine candidate,’ Mountain West News Bureau
“In those animals that did not receive the vaccine, we saw high levels of virus present in the lungs, present in the trachea, present in samples that we took from various organs within the body. In the groups that were vaccinated, there’s no evidence of adverse effects and no evidence the disease has actually been occurring,” said Ray Goodrich, director of the Infectious Disease Research Center at Colorado State University.
June 25: ‘Promising results mean coronavirus vaccine trial could start by August,’ HealthDay News
“Animal studies of a potential COVID-19 vaccine have been so encouraging that researchers plan to speed up testing of the vaccine in humans,” the article said.
June 25: ‘Two doses of Oxford University coronavirus vaccine tested on pig,’ Oxford Mail
June 25: ‘Use of statins linked to lower death rate in COVID-19 patients: Study,’ Press Trust of India
“According to the researchers, statins may serve such a purpose because these drugs slow the progression of lung injury in animals, improve immune cell responses, and strongly reduce inflammation, which is likely responsible for severe Covid-19 complications such as organ damage,” the article said.
June 25: ‘The race for a COVID-19 vaccine: What’s ahead,’ Scope
June 25: ‘Coronavirus: How long does it really take to get a vaccine ready? We explain to you the process,’ The Times of India
“Only if a certain vaccine surpasses the animal testing phase is it allowed to proceed to clinical trials on humans,” the article said.
June 25: ‘Coronavirus vaccines are coming, but when will they arrive?’ USC News
“It usually takes about two years to bring a new drug to market, even after large clinical trials are underway, although priority drugs can advance faster, she said. It’s an elaborate process, involving lab tests, animal experiments and human trials, plus ensuring that adequate production facilities, quality control and distribution chains are in place,” the article said.
June 24: ‘COVID-19 vaccine candidate proceeds to animal testing,’ Kazan Federal University
June 24: ‘Coronavirus: “Significant step” in development of vaccine for animals,’ The Independent
June 24: ‘Duke researchers discuss timeline for COVID-19 vaccine, clinical trials,’ WRAL
“One Duke researcher in Singapore who is working on a vaccine said they are in the animal testing phase right now, but hope to move to clinical trials soon,” the report said.
June 23: ‘Could we get a vaccine for cats before people? Two potential COVID-19 animal treatments are shown to eliminate the virus in lab tests,’ Daily Mail
June 23: ‘Progress in monoclonal antibodies for the treatment and prevention-of Covid-19,’ Forbes
“The antibodies were introduced in the mice 12 hours after the viral challenge. The experiment showed that the antibody treatment reduced the amount of virus in the animals by 32.8% for one of the antibodies and 26% for the other, when compared to a control group three days post-infection,” the article said. “The animals treated with each antibody also had fewer lung lesions than the placebo control animals.”
June 23: ‘Nearly 150 potential coronavirus vaccines are being developed globally,’ Newsweek
“The studies demonstrated that vaccination with INO-4800 generated robust binding and neutralizing antibody as well as T cell responses in mice and guinea pigs,” Inovio Pharmaceuticals said in a statement.
June 23: ‘ACE2 and TMPRSS2 variation in savanna monkeys (Chlorocebus spp.): Potential risk for zoonotic/anthroponotic transmission of SARS-CoV-2 and a potential model for functional studies,’ PLOS One
June 23: ‘Pig trial of AstraZeneca’s COVID-19 vaccine shows promise with two shots,’ Reuters
June 23: ‘Hamsters protected from COVID-19 with convalescent serum; develops immunity: Study,’ Science Times
June 23: ‘Scientists make step forward in development of COVID-19 animal vaccines,’ University of Plymouth
June 22: ‘Animal antibodies for COVID-19,’ European Animal Research Association
June 22: ‘U of G study focusing on risk of COVID-19 to pets,’ GuelphToday
June 22: ‘Going back in time for an antibody to fight COVID-19,’ Nature
“The next steps will be to test individual antibodies and antibody cocktails in animal models, to determine whether they offer protection, and then to assess their safety and effectiveness in human clinical trials,” the article said.
June 22: ‘Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2,’ News Medical
“In this new study, the research group from The Pirbright Institute, the Jenner Institute of the University of Oxford, University of Surrey, Rutherford Appleton Laboratory Harwell Oxford and Public Health England decided to test the immunogenicity of either one or two doses of AZD1222 vaccine in mice and pigs in order to inform clinical development additionally,” the article said.
June 22: ‘Thai trials of COVID-19 vaccine reach make-or-break stage,’ Reuters
“Thai scientists administered a second dose of an experimental COVID-19 vaccine to monkeys on Monday, looking for another positive response to enable clinical trials in humans as early as October,” the report said.
June 22: ‘Monkeys, baboons to be used for COVID-19 vaccine study,’ SBG San Antonio
June 22: ‘Thailand’s COVID-19 vaccine trial on monkeys successful: Minister,’ Xinhua News Agency
June 20: ‘Corona battle: IVRI in the forefront, testing both human and animal samples,’ Hindustan Times
June 20: ‘Antibodies from convalescent plasma protect against COVID-19,’ The Hindu
“A team of scientists led by Dennis R. Burton from the Scripps Research Institute has discovered that neutralising antibodies present in the blood of COVID-19 infected who have recovered offers powerful protection against novel coronavirus in animals,” the article said.
June 19: ‘In China’s vaccine race, shortage of monkeys and weekends,’ Agence France-Presse
June 19: ‘Cats and dogs “could spark a second wave of coronavirus cases” experts now warn,’ Daily Mirror
June 19: ‘Pirbright: SARS-CoV-2 has ability to enter animal cells in lab setting,’ Farm Journal’s PORK
June 19: ‘Wildlife trade spreads coronaviruses as animals get to market,’ The New York Times
June 18: ‘Expert advice on recovering and resuming animal research,’ Charles River Laboratories
June 18: ‘Could our pets trigger a second wave of COVID-19? Scientists warn that animals could become “reservoirs” of the virus even after it is eradicated in humans,’ Daily Mail
June 18: ‘Monoclonal antibody against COVID-19 enters clinical trial,’ Medical Xpress
“This is also the first clinical trial in the world of therapeutic mAb in healthy people after evaluation in a non-human primate model,” the report said.
June 18: ‘SARS-CoV-2 transmission to animals: Monitoring needed to mitigate risk,’ Medical Xpress
June 18: ‘RI state veterinarian: “Small risk” owners can infect pets with COVID-19,’ WPRI
June 17: ‘Scientists isolate powerful SARS-CoV-2 -neutralizing antibodies from COVID-19 patients,’ News Medical
“Preliminary results in animal studies have so far proven successful,” the article said.
June 17: ‘Cows help with COVID-19 treatment, no bull,’ NPR
June 17: ‘How humanity unleashed a flood of new diseases,’ The New York Times
“What do Covid-19, Ebola, Lyme and AIDS have in common? They jumped to humans from animals after we started destroying habitats and ruining ecosystems,” the story said.
June 17: ‘S. Korea to conduct tests of COVID-19 vaccine, treatment candidates on monkeys this month,’ Yonhap News Agency
June 16: ‘Beating back the coronavirus: Harvard researchers look for a cure,’ Boston Herald
“Wyss [Institute] researchers have already identified promising compounds that are currently being tested by collaborating labs in human organ chip technologies and animal models, and the team is continuing to evaluate many more drugs,” the report said.
June 16: ‘FDA cautions pet owners about infecting their pets in new video,’ CNN
June 16: ‘Human trials expected to start next month for COVID-19 treatment derived from cows’ blood,’ CNN
June 16: ‘New evidence that malaria drug has no antiviral effect on COVID-19,’ Knowridge
“In a new study, researchers examined the antiviral effect of hydroxychloroquine in macaques (a type of monkey) infected with the COVID-19 virus, used alone or in combination with drug azithromycin,” the report said.
June 16: ‘Researchers identify potent antibody cocktail to treat COVID-19,’ ScienceDaily
“The study demonstrates the rapid process of isolating, testing and mass-producing antibody therapies against any infectious disease by using both genetically engineered mice and plasma from recovered COVID-19 patients,” the press release said.
June 16: ‘Developing the coronavirus vaccine supply chain,’ Supply Chain Dive
“After lab testing, researchers move to animal testing and ultimately to humans,” the article said.
June 15: ‘Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model,’ Science
June 15: ‘Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail,’ Science
June 15: ‘Super-potent human antibodies protect against COVID-19 in animal tests,’ Scripps Research
June 15: ‘Indonesian COVID-19 vaccines to undergo strict human, animal testing,’ The Jakarta Post
“Eijkman Institute director Amin Soebandrio said animal testing was to ensure that the vaccine’s antigens could form antibodies in humans, which could help protect them from COVID-19. … Animal rights organizations have voiced their objections to animal testing despite researchers ensuring that they will adhere to ethical norms,” the article said.
June 15: ‘Search for COVID-19 vaccine includes animal tests,’ VOA Learning English
June 14: ‘Hydroxychloroquine ineffective in animal SARS-CoV-2 infection,’ News Medical
June 14: ‘Coronaviruses extremely widespread in wildlife trade: Study,’ The Sydney Morning Herald
June 13: ‘Future COVID-19 treatments made possible by animal testing,’ Health ThoroughFare
June 13: ‘The race to find a COVID-19 vaccine: The INO-4800 study participation at the University of Pennsylvania,’ TrialSite News
“INO-4800 evidence has been well-tolerated first in preclinical studies in mice, and then in the first cohort of 40 participants in the Phase I stage of the study,” the article said.
June 12: ‘As pressure for vaccine builds, regulators may face difficult decision,’ ABC News
“Moderna Inc., which is developing what is considered to be the lead candidate, for example, was given permission to begin testing in humans before waiting until testing in animals was complete. Animal testing is ongoing,” ABC reported.
June 12: ‘Latin American scientists join the coronavirus vaccine race: “No one’s coming to rescue us,”’ Nature
University of Sao Paulo immunologist Gustavo Cabral de Miranda’s “group is starting animal testing, and some other COVID-19 vaccine candidates in preclinical evaluation are following a similar approach,” the article said.
June 12: ‘Hydroxychloroquine shows no antiviral effect on SARS-Cov-2 in non-human primate models,’ News Medical
June 12: ‘Moderna COVID-19 vaccine appears to clear safety hurdle in mouse study,’ Reuters
June 12: ‘NC A&T, WSSU each receive $1 million to fight COVID-19,’ Triad Business Journal
“N.C. A&T said it plans to use the funding for multiple projects, from studies in both food and animal testing, affordable fever detection in K-12 schools, ways to cut down death rates among the elderly in assisted living facilities and the development of a nanoparticle that can kill the virus,” the article said.
June 12: ‘LSU working on “unique” COVID-19 vaccine; applying for expedited funding,’ WBRZ
“We believe that animal studies, including mice and monkeys, will show that the LSU patented vaccine is much more efficacious in conferring long-term responses to the virus,” Dr. Gus Kousoulas said.
June 11: ‘Can new drug help speed up recovery from COVID-19?’ CGTN
“Remdesivir is an antiviral medication developed initially by U.S. biopharmaceutical company Gilead Sciences to treat Ebola. It wasn’t effective, but during animal testing it had shown promise treating SARS and MERS, both of which are coronaviruses,” the report noted.
June 11: ‘COVID-19 vaccine from China’s Sinopharm clears animal tests,’ FierceBiotech
June 11: ‘Future COVID-19 treatments could be thanks to cows, llamas, and pangolins,’ Inverse
June 11: ‘Potential COVID-19 vaccine from China shows promise in animal trials,’ The Hill
June 11: ‘UConn researcher talks vaccine realities in an unprecedented time,’ UConn Communications
“This is a significant concern because despite many years of research on other human coronaviruses such as SARS‑CoV and MERS‑CoV, no vaccines of any kind have been approved. Another major concern is that some experimental vaccine studies in animal models suggest that insufficient protective immunity against coronaviruses such as SARS‑CoV may induce enhanced susceptibility to respiratory disease,” UConn vaccine researcher Paulo Verardi said. “In other words, inadequate or weak vaccines may not only lead to poor protection but also to vaccine-enhanced disease in COVID‑19 patients.”
June 10: ‘Ending an epidemic,’ Harvard Magazine
“In an experiment led by Castle professor of medicine and professor of immunology Dan Barouch, animals exposed to the virus a second time five weeks later developed no clinically observable symptoms and displayed immunologic control of the disease,” the article said.
June 10: ‘Veterinary labs continue to support COVID-19 testing,’ Journal of the American Veterinary Medical Association
June 10: ‘Vaccine makers hedge bets on which one will emerge as effective and safe,’ NPR
“We have a lot of confidence based on what we’ve see so far based on our animal modeling that the vaccine will work,” said Gregory Glenn, president of research and development at Novavax.
June 10: ‘Daewoong finds niclosamide effective against COVID-19 in animal tests,’ Pharmaceutical Technology
BREAKING NEWS: June 10: ‘Study: Remdesivir prevented lung damage in monkeys infected with COVID-19,’ RTTNews
“Gilead Sciences’ experimental COVID-19 drug, remdesivir, reduced viral load and prevented lung disease in macaques infected with the coronavirus, according to a study published in the medical journal Nature. … Remdesivir, an antiviral drug that was initially created to treat Ebola, is the first drug to show improvement in COVID-19 in human trials,” the report said.
June 9: ‘Novavax announces high neutralizing antibody titers in COVID-19 vaccine,’ BioCentury
“In a June 2 presentation, Novavax showed that NVX CoV2373 induced animals to produce neutralizing antibodies against SARS-CoV-2 and that titers increased at least eightfold following a second vaccination. The company also showed that Matrix-M enhances immunogenicity,” the article noted.
June 9: ‘Mini-organs push along Covid-19 and other virus research’ Knowable Magazine
“Organoids can do a lot — but not everything, [Josef] Penninger [a medical geneticist at the University of British Columbia in Vancouver] acknowledges: ‘This will not replace animal models,”’ the article said.
June 9: ‘LegoChem licenses in COVID-19 treatment candidates,’ Korea Biomedical Review
“When judged based on animal test results, candidates introduced through this technology transfer are likely to be developed as therapeutic agents that are effective against various viruses that have undergone mutation,” LegoChem Bioscience CEO Kim Yong-joo said.
June 9: ‘Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2,’ Nature
June 9: ‘Gilead’s remdesivir prevents lung damage in COVID-19 study on monkeys,’ Reuters
June 9: ‘South Korea’s Daewoong Pharmaceutical says anti-parasitic drug effective against coronavirus in animal tests,’ Reuters
June 9: ‘Coronavirus rips through Dutch mink farms, triggering culls to prevent human infections,’ Science
June 9: ‘If approved, COVID-19 vaccine patch could eliminate painful shot,’ Scripps Media
“Scientists at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center have created a fingertip-sized skin patch that is also showing promising results in animal testing,” the article said.
June 9: ‘Can a vaccine for COVID-19 be developed in record time?’ The New York Times
The Times held a virtual round table discussion with a virologist, a vaccine scientist, an immunologist and oncologist, a biotech scientist and inventor, and a former head of the Food and Drug Administration.
“An ideal animal model is one that reproduces the human disease as closely as possible — in which, for example, clinical signs resembling symptoms in humans are observed, virus replication is observed in similar organs, immune response mirrors that in humans and so on. In addition, an animal model is often used to demonstrate whether a virus can be transmitted from an infected to an uninfected animal,” said Susan Weiss, a microbiology professor at the University of Pennsylvania. “Scientists use animal models to understand how the virus causes disease.”
June 9: ‘With an internet of animals, scientists aim to track and save wildlife,’ The New York Times
June 9: ‘Update: China Focus: Chinese researchers publish inactivated COVID-19 vaccine’s effect on animals,’ Xinhua News Agency
June 8: ‘Niclosamide proves effective against COVID-19 in Daewoong’s animal test,’ Business Korea
June 8: ‘Experts optimistic in search for COVID-19 vaccine,’ HealthDay News
Animal research is an important part of the vaccine testing process.
June 8: ‘Two cats are first US pets to be sickened with COVID-19,’ HealthDay News
June 8: ‘Does CSF antibody testing confirm coronavirus in the brain?’ Medscape Medical News
“It’s not clear how the virus invades the brain, said [Dr. Karima] Benameur. Some speculate it could be through the olfactory nerve, which might explain why some patients lose their sense of taste and/or smell,” the article said. “Benameur noted that animal research shows that when the virus is injected into nose fibers, it can travel to the brain.”
June 8: ‘The race for a coronavirus vaccine runs on horseshoe crab blood,’ Smithsonian Magazine
June 8: ‘For experts who study coronaviruses, a grim vindication,’ Undark Magazine
“Scientists had for years been finding viral strains in bats and other animals that were genetically similar to the virus behind the SARS epidemic. But sequence data has its limits,” the article said.
June 7: ‘The next pandemic is coming – and sooner than we think, thanks to changes to the environment,’ Australian Broadcasting Corporation
“Nearly all emerging pathogens like COVID-19 come from ‘zoonotic transfer’ — essentially, when a virus present in animals jumps to infect humans. … Zoonotic diseases are particularly complex because they overlap multiple sectors — environment, agriculture, and health — that are often siloed from one another,” the article said. “Dr. [Simon] Reid says his dream project would bring together researchers with knowledge of across multiple fields, including from human and animal medicine, ecology, sociology, microbiology and those who study the transmission of pathogens in humans, wildlife, and livestock.”
June 7: ‘Fujifilm says COVID-19 drug research might get extended till July,’ Republic World
“The trial involved the drug to be administered for a maximum of 14 days to coronavirus patients between 20 and 74 years old with mild pneumonia. The study excludes pregnant women due to side effects shown in animal testing, [a Fujifilm spokesman] added,” the report said.
June 7: ‘Study shows COVID-19 can spread easily between cats,’ The Asahi Shimbun
June 6: ‘Coronavirus: This is not the last pandemic,’ BBC News
“Many scientists agree that our behaviour – particularly deforestation and our encroachment on diverse wildlife habitats – is helping diseases to spread from animals into humans more frequently,” the article said.
June 6: ‘China begins phase 1 clinical trials of neutralizing antibody treatment for COVID-19,’ Global Times
“The phase I clinical trial will test the safety and dosage of the neutralizing antibody among healthy people, and this is a clinical trial for the world-first neutralizing antibody treatment against COVID-19 among healthy people after non-human primate experiments,” the article said.
June 5: ‘Daewoong reports progress in animal testing of tapeworm treatment medicine as COVID-19 medication,’ Aju Business Daily
June 5: ‘Sorrento Therapeutics stock surges after COVID-19 drug breakthrough,’ Idaho Reporter
“STI-4398 COVIDTRAP protein and STI-1499 neutralizing antibody have shown efficacy in an in vitro cellular infection model for SARS-CoV-2 established in our laboratory and these results justify now the progression into animal studies. We are planning to submit all preclinical data for scientific publication in the next two to three months,” said Dr. Slobodan Paessler.
June 5: ‘Coronavirus vaccine developers wary of errant antibodies,’ Nature
“I think the way forward is to take it seriously, do some animal studies, show you don’t have enhancement, monitor during the trial,” Novavax President of R&D Gregory Glenn said.
June 5: ‘Frozen cells and empty cages: researchers struggle to revive stalled experiments after the lockdown,’ Nature
The article focuses on the gradual resumption of research in animal laboratories in the U.S. as the preliminary stages of reopening get underway.
June 5: ‘The biggest mystery: what it will take to trace the coronavirus source,’ Nature
“SARS-CoV-2 came from an animal but finding which one will be tricky, as will laying to rest speculation of a lab escape,” Nature noted.
June 5: ‘This cow’s antibodies could be the newest weapon against COVID-19,’ Science
June 5: ‘Researchers study how often household pets contract COVID-19,’ The Daily Evergreen
June 4: ‘K-State veterinary research team receives federal grant,’ KSNT
“The directors also plan to expand the program by obtaining additional grants that they can use to begin coronavirus research,” the report said.
June 4: ‘A German shepherd is first dog in the U.S. to test positive for the coronavirus,’ National Geographic
BREAKING NEWS: June 4: ‘Crab blood can save your life, but not the synthetic stuff,’ Popular Mechanics
“Horseshoe crab blood and rFC are both used to screen injectable drugs for the presence of toxic contamination. The crabs’ unique blood chemistry leads to unmistakably clear reactions to endotoxins, which include E. coli and salmonella,” the article said.
BREAKING NEWS: June 4: ‘Tyson the alpaca takes heavyweight role in search for coronavirus vaccine,’ Reuters
Take a look at the coronavirus research Tyson the alpaca is helping with. “We know that it is the antibodies that are directed to the same very, very precise part of the virus that are important and that is what we have engineered with this antibody from Tyson,” said Gerald McInerney, head of a team at the Karolinska Institute. “In principle, all the evidence would suggest it will work very well in humans, but it is a very complex system.”
What’s next for Tyson? Life on his farm in Germany.
June 4: ‘Does Fido have coronavirus? Tufts researchers are testing hundreds of animals to find out,’ The Boston Globe
June 4: ‘The coronavirus pandemic claims another victim: Medical research for deadly rare diseases,’ The Washington Post
This article highlights the impact the COVID-19 pandemic is having on research using animal models, including research to find cures for rare diseases.
June 4: ‘A coronavirus vaccine could require you to get two shots. Here’s why,’ USA Today
“Phase 1 studies look at both dose size and, if animal studies suggest two doses might be needed, then they also look at one dose versus two doses,” said Dr. Kelly Moore, associate director of immunization education for the Immunization Action Coalition.
June 3: ‘The keys to speed in race for vaccine, and its perils,’ Bloomberg
“After testing a vaccine in animals, developers must show it’s safe and effective in humans,” the article said.
June 3: ‘COVID-19 drug shows 100-fold drop in viral load in animal testing, South Korea’s Celltrion says,’ Fox News
June 3: ‘First US dog in NY contracts COVID-19; NC pug didn’t actually have it, experts say,’ Miami Herald
June 3: ‘Tests for coronavirus vaccine need this ingredient: Horseshoe crabs,’ The New York Times
June 3: ‘Animal medicine might play a crucial role in developing the sought-after coronavirus vaccine,’ The Telegraph
June 3: ‘WHO resumes study of hydroxychloroquine for treating COVID-19,’ Time
“Studies in animals and cell cultures in the lab show it may also help suppress the aggressive immune reaction that doctors have seen in some patients’ lungs and respiratory systems. That suggests that by the time a COVID-19 patient is hospitalized, it might be too late for hydroxychloroquine to help, since the infection is already well underway,” the report said.
June 2: ‘Household cat in Minnesota confirmed with virus that causes COVID-19,’ KELO.com
June 2: ‘Does interferon therapy work in COVID-19?’ News Medical
“The potential for the use of interferons in coronavirus infections was examined in the earlier outbreaks of SARS and MERS. In vitro experiments showed that interferons did have antiviral activity on the SARS-CoV, especially IFN-β and IFN-γ, and for IFN- β, against MERS-CoV as well,” the article said. “Follow-up animal experiments showed that IFN-β had higher antiviral activity against MERS CoV compared to the lopinavir-ritonavir combination.”
June 2: ‘New gene-edited lab mice are especially good at catching COVID-19,’ OneZero
June 2: ‘Ibuprofen to be tested as treatment to reduce COVID-19 breathing problems,’ Press Association
“This is very promising. But of course it is an animal study, so we want to translate that really compelling result into humans,” King’s College London neuroimaging and psychopharmacology professor Mitul Mehta told the PA news agency.
June 2: ‘South Korea expects human trials of Celltrion’s potential COVID-19 treatment in Europe,’ Reuters
The company will move to clinical trials after testing in animals.
June 2: ‘Carver County cat is first animal in Minnesota diagnosed with COVID-19,’ St. Paul Pioneer Press
June 2: ‘Monkeys, ferrets offer needed clues in COVID-19 vaccine race,’ The Associated Press
June 2: ‘Confirmation of COVID-19 in pet dog in New York,’ USDA Animal and Plant Health Inspection Service
June 1: ‘Celltrion achieves initial progress in animal testing of candidates for antibody treatment,’ Aju Business Daily
June 1: ‘SARS-CoV-2 looks like a hybrid of viruses from two different species,’ Ars Technica
June 1: ‘What to know about potential COVID-19 treatment remdesivir,’ Healthline
“Even before COVID-19, Gilead had tested remdesivir against other coronaviruses — including those that cause SARS and MERS — in laboratory and animal studies,” the report noted.
June 1: ‘What’s the risk that animals will spread the coronavirus?’ Nature
June 1: ‘Celltrion’s Covid-19 antibody therapy reduces viral load in animal tests,’ Pharmaceutical Technology
June 1: ‘Operation Warp Speed selects billionaire scientist’s COVID-19 vaccine for monkey tests,’ Science
June 1: ‘Antibody injections could fight COVID-19 infections – an infectious disease expert explains the prospects,’ The Conversation
“Why are animal models so important? Because there are many other factors that could affect antibody efficacy in a living organism that can’t be simulated in a petri dish,” the article said. “For example, how long are mAbs functional in the body and are they safe? Animal models can provide preliminary safety data. Beyond animal models, a key mAb property to consider is whether it can be efficiently manufactured in a stable, safe form for human use.”
May 31: ‘Animals at university research labs still get care during the pandemic — but scores have been euthanized to conserve “critical resources,”’ Chicago Tribune
May 31: ‘South Korea’s Celltrion aims to start in-human COVID-19 drug trial in July,’ Reuters
“South Korea’s Celltrion Inc said on Monday its experimental treatment of COVID-19 demonstrated an up to 100-fold reduction in viral load of the disease in animal testing, saying it aims to start in-human clinical trials in late July,” the report said.
May 30: ‘The search for an animal model to study COVID-19,’ The Hindu
May 30: ‘Russia approves flu drug’s use against COVID-19,’ The Wall Street Journal
“Japan approved Avigan as a flu drug in 2014. It has only been used as a backup treatment and not given to most patients, partly because animal testing showed it could potentially cause birth defects,” WSJ reported.
May 29: ‘USDA says testing “unable to verify infection” in dog presumed to have COVID-19,’ ABC News
May 29: ‘Scientists develop COVID-19 test for dolphins, sea turtles,’ E&E News
May 29: ‘Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19,’ Heart Rhythm
“In this study we used optical mapping to demonstrate the arrhythmic effects of [hydroxychloroquine (HCQ)] on [guinea pig] and rabbit hearts perfused with the upper therapeutic serum dose of HCQ (1000 ng/mL),” the authors wrote.
May 29: ‘Five facts about seeking a COVID-19 vaccine,’ RealClearPolicy
Fact #2: “Animal research suggests COVID-19 survivors may gain immunity.”
May 29: ‘Rapid COVID-19 vaccine development,’ Science
“It will be important to demonstrate the potential for vaccine efficacy in early-phase clinical studies by measuring the induction of neutralizing antibodies and in animal models by demonstrating protection against virus replication and disease,” the article said.
May 29: ‘Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2,’ Science
May 29: ‘Evolution of pandemic coronavirus outlines path from animals to humans,’ ScienceDaily
May 29: ‘Can veterinarians save us from the next pandemic?’ The Hill
May 29: ‘COVID-19 human challenge studies: ethical issues,’ The Lancet
“Although vaccines are usually associated with very low risks, experimental vaccines might not protect participants and, in some cases, might even increase the severity of disease among those who are subsequently infected. These outcomes have occurred, for example, for vaccines against respiratory syncytial virus (46) and dengue virus, (47) in some cases resulting in small numbers of deaths among participants in vaccine research,” the article said. “This kind of danger might apply to coronavirus vaccines, because vaccine-enhanced disease has been observed in animal challenge studies with coronaviruses (12).”
May 29: ‘Research labs to become operational in coming weeks,’ The Pitt News
“Since each lab is different, the procedures will vary. For example, the animal research labs cannot allow researchers into the lab past a certain time or it will interfere with the circadian rhythms of the animals — making it difficult to have multiple shifts,” the report said.
May 28: ‘Researchers look at role of pets in COVID-19 transmission,’ Journal of the American Veterinary Medical Association
May 28: ‘Federal government rents monkeys from Denver business to fight COVID-19,’ LancasterOnline
May 28: ‘Ferritin heavy chain protein shows promise as a potential SARS-CoV-2 vaccine or antiviral,’ News Medical
“Research on COVID-19 patient samples has shown the presence of two antibodies that inhibit viral RBD-ACE2 binding. Animal experiments have shown that these could reduce the viral load in the lungs of infected mice,” Dr. Liji Thomas wrote.
May 28: ‘COVID-19 vaccine developers search for antibodies that “first do no harm,”’ Scientific American
Scientists “are connecting hypothetical dots based on past studies of experimental vaccines for previous outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), in which some immunized animals developed more severe disease,” the report said.
May 28: ‘Novartis inks deal to make experimental coronavirus vaccine,’ The Wall Street Journal
“The Swiss drugmaker’s gene therapy unit AveXis is already making test batches of the vaccine and plans to start producing doses later in the summer that can be used for a clinical trial, said Dave Lennon, the unit’s president. … The Novartis unit has so far committed to manufacture doses for animal studies and a phase 1 trial, free of charge, Dr. Lennon said,” WSJ reported.
May 27: ‘Dogs sniff out coronavirus “far better than machines or tests,”’ Alliance for Science
May 27: ‘Chinese researchers find human neutralizing antibody targeting COVID-19 receptor binding site,’ Global Times
Researchers working with rhesus macaques published results in Nature on May 26.
May 27: ‘UTSA professor’s “rabbit fever” vaccine to be tested against coronavirus,’ San Antonio Express-News
May 27: ‘A small number of monkeys could help millions of people: Coronavirus vaccine testing,’ Speaking of Research
May 27: ‘US company trials coronavirus vaccine candidate in Australia,’ The Associated Press
Novavax started clinical trials for a coronavirus vaccine candidate, NVX-CoV2373, in Australia. Animal tests showed positive results in low doses.
May 27: ‘Coronavirus questions: 10 things we still urgently want to know about COVID-19 in the next 100 days,’ USA Today
“Oxford University in England and Maryland-based vaccine company Novavax seem ahead of the global race as their vaccine candidates have shown success in animal trials,” USA Today noted.
May 26: ‘Nature publishes preclinical characterization and primate efficacy data on Junshi Biosciences’ COVID-19 neutralizing antibodies,’ Globe Newswire
May 26: ‘A human neutralizing antibody targets the receptor binding site of SARS-CoV-2,’ Nature
Researchers working with rhesus macaques found the first human neutralizing monoclonal antibody for COVID-19.
May 26: ‘Merck, one of Big Pharma’s biggest players, reveals its COVID-19 vaccine and therapy plans,’ Science
Merck Research Laboratories President Roger Perlmutter reportedly said the company plans to look at EIDD-2801’s cancer-causing potential in reproductive and developmental biology animal studies.
May 26: ‘Coronavirus: why we’re using llamas to help fight the pandemic,’ The Conversation
May 26: ‘Taxpayers paid to develop remdesivir but will have no say when Gilead sets the price,’ The Washington Post
“In remdesivir’s case, government researchers narrowed the search from 1,000 compounds to the chemical that would become remdesivir, confirmed its potency in laboratory tests, tested it in monkeys, and finally sponsored a pivotal clinical trial in humans,” the report said.
May 26: ‘COVID-19 vaccine development,’ U.S. Government Accountability Office
“In the preclinical phase, researchers use cells and animals to assess safety and produce evidence of clinical promise, evaluated by the candidate’s ability to elicit a protective immune response,” a GAO report said.
May 25: ‘Thailand enters global race for vaccine with trials on monkeys,’ Agence France-Presse
May 25: ‘“A key milestone”: COVID-19 vaccine “highly effective” in ferrets, says VIDO-Intervac,’ Saskatoon StarPhoenix
May 25: ‘Canadian coronavirus vaccine candidate delivers promising results in animal tests,’ The Globe and Mail
May 24: ‘Who’s leading the race? A guide to coronavirus vaccines in the pipeline,’ Australian Broadcasting Corporation
“While it will be some months before we know whether any of the proposed vaccines are effective, initial safety trials and encouraging animal studies show promising early signs,” ABC noted.
May 24: ‘How animal research at UGA is adapting to COVID-19,’ The Red & Black
May 22: ‘VIDO-Intervac wraps up animal phase of COVID-19 vaccine testing,’ CKOM News
May 22: ‘SARS-CoV-2 transmission in cats,’ Outbreak News TV
May 22: ‘The coronavirus vaccine is on track to be the fastest ever developed,’ The New Yorker
“In mice, the vaccine provided full protection against viral replication in the lungs, which researchers tested by giving mice the vaccine and then deliberately infecting them with the virus,” The New Yorker reported about Moderna’s experimental vaccine. “(Scientists place a small drop of virus-laced fluid over the mouse’s nostrils. Similar trials on rhesus macaques are about to start.)”
May 22: ‘Coronavirus vaccine shows promising early results in China,’ The New York Times
The report said:
“‘This is promising data, but it’s early data,’ said Dr. Dan Barouch, director of vaccine research at Beth Israel Deaconess Medical Center in Boston, who was not involved in the work. ‘Over all, I would say this is good news.’
… And on Wednesday, Dr. Barouch and his colleagues published a study showing their prototype vaccine protected monkeys from coronavirus infection.”
May 21: ‘Airport dogs could sniff out coronavirus,’ CNN
May 20: ‘NIH supported MMRRC repository providing COVID-19 related mouse models for research,’ Mutant Mouse Resource & Research Centers
May 20: ‘New studies show that developing a coronavirus vaccine should be possible,’ NPR
“Three studies published Wednesday suggest it should be possible to come up with a coronavirus vaccine — tests performed on animals have shown the right results to prove a vaccine could be possible,” NPR reported.
May 20: ‘Inovio says COVID-19 vaccine produces antibodies in mice, guinea pigs,’ Reuters
May 20: ‘DNA vaccine protection against SARS-CoV-2 in rhesus macaques,’ Science
May 20: ‘Human viruses can jump into animals, too—sowing the seeds of future epidemics,’ Scientific American
BREAKING NEWS: May 20: ‘Two studies suggest COVID-19 antibodies provide immunity,’ The Boston Globe
Two studies published in Science found antibodies to SARS-CoV-2 provide some level of immunity in rhesus macaque monkeys, though it is unknown how long protection lasts.
May 20: ‘Wistar Institute coronavirus vaccine shows signs of eliciting immune response in animals,’ The Daily Pennsylvanian
May 20: ‘Vaccines can protect against COVID-19 in nonhuman primates, study says,’ The Harvard Gazette
May 20: ‘Two new studies suggest COVID-19 antibodies provide immunity,’ The Hill
“In one of the studies, nine rhesus macaque monkeys, which share 93 percent of the same DNA as humans, were injected with SARS-CoV-2, the virus that causes COVID-19. The virus quickly spread and all of the animals developed viral pneumonia, though all of them recovered within 28 days,” The Hill reported.
May 20: ‘Progress reported for coronavirus vaccines from Jefferson and Wistar, skepticism about Moderna,’ The Philadelphia Inquirer
“Our partnership with Bharat Biotech will accelerate our vaccine candidate through the next phases of development,” Jefferson Vaccine Institute Director Matthias Schnell said. “We will be able to complete animal testing and move to a phase 1 clinical trial [in humans] rapidly.”
May 20: ‘A new entry in the race for a coronavirus vaccine: Hope,’ The New York Times
“Animal studies have raised expectations, too. Researchers at Beth Israel Deaconess Medical Center on Wednesday published research showing that a prototype vaccine effectively protected monkeys from infection with the virus,” the article said. “The findings will pave the way to development of a human vaccine, said the investigators.”
May 20: ‘How would a drug to potentially treat the coronavirus be developed?’ Utah Public Radio
“Once they’ve determined an animal’s coronavirus symptoms, [Utah State University Professor Brett] Hurst said they can treat the animals with the drugs that proved to be successful in the human-cell model,” the report said.
May 20: ‘COVID-19 vaccine possible by early 2021, local expert says,’ WWL-TV
“Another thing that was similar to humans is that most of the animals [primates] didn’t get sick, visibly ill, but there were a couple that did,” said Dr. Skip Bohm, chief veterinary medical officer of the Tulane National Primate Research Center.
May 19: ‘Coronavirus vaccine trials have delivered their first results — but their promise is still unclear,’ Nature
“One way to find out whether vaccines can prevent transmission would be to study them in animals that are naturally susceptible to the virus and seem capable of spreading it, such as ferrets and hamsters, says [University of Pittsburgh Center for Vaccine Research aerobiologist Douglas] Reed,” the article said.
May 18: ‘As researchers at Northwestern and elsewhere scramble to find a treatment for COVID-19, they hope this time the money won’t run out before the next threat hits,’ Chicago Tribune
“When researchers identify the genetic sequence of a protein or enzyme that is essential to the virus’s replication, they then look for a compound that blocks it, called the inhibitor. The compounds are developed into a drug that not only lasts long enough in the body to kill the virus but is also nontoxic,” the report said. “Only then can it move to animal trials and, eventually, human trials.”
May 18: ‘CureVac ramps up COVID-19 mRNA vaccine effort as Moderna analysts raise questions about animal data,’ FierceBiotech
“CureVac said late last week that its lead COVID-19 vaccine candidate generated ‘high levels’ of virus-neutralizing titers in animal models and that it ‘has the potential to induce a strong immunologic response to neutralize SARS-CoV-2,'” the report said.
May 18: ‘Lawrence Livermore scientists part of three-institution team working to develop vaccine for tularemia,’ Lawrence Livermore National Laboratory
Two Lawrence Livermore National Laboratory researchers will collaborate with scientists from the University of New Mexico and the Tulane National Primate Research Center.
“Lab researchers see the [nanolipoprotein particles] NLPs platform as a flexible tool that can broadly be applied to developing vaccines for different pathogens,” the press release said.
May 18: ‘Moderna’s coronavirus vaccine shows promise in early results,’ Live Science
The article said:
“‘These interim phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 µg,’ Dr. Tal Zaks, the chief medical officer at Moderna, said in the statement. When combined with data from the mouse study, these results ‘substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.’”
May 18: ‘Early data show Moderna COVID-19 vaccine generates immune response,’ STAT News
“The neutralizing antibody and safety results from the Phase 1 clinical study are promising for the Moderna mRNA vaccine candidate and supportive to proceed forward with the planned Phase 2 studies,” RenovaCare Chief Scientific Officer Robin Robinson told STAT.
The health-oriented news website reported: “Vaccination with the candidate vaccine, provisionally labeled mRNA-1273, also prevented viral replication in the lungs of mice in preclinical testing, the [Moderna’s] statement said.”
May 18: “Why Rhesus monkeys are used for most vaccine trials,” The Times of India
May 18: ‘Tulane scientists discuss ongoing coronavirus research including plans to vaccinate animals,’ WVUE
May 18: ‘Chinese researchers identify highly potent neutralizing antibodies against COVID-19,’ Xinhua News Agency
“Chinese researchers have successfully identified multiple highly potent neutralizing antibodies against SARS-CoV-2, the virus that causes COVID-19, from convalescent plasma by high-throughput single-cell sequencing, according to a new study published in Cell on Sunday. … New results from animal studies showed that neutralizing antibodies provide a potential cure for COVID-19 as well as a means for short-term prevention, which marks a major milestone in the fight against the pandemic,” the report said.
May 15: ‘Coronavirus vaccine: Macaque monkey trial offers hope,’ BBC News
BREAKING NEWS: May 15: ‘Researchers use cows to develop antibody treatment,’ CNN
“Scientists at SAb Biotherapeutics are planning to start studies this summer on coronavirus treatments created by using antibodies derived from cows with genetically engineered human immune systems,” CNN reported. Watch the video segment.
May 15: ‘Coronavirus research: The known “risk” scientists are taking in race for COVID-19 vaccine,’ Nine News Sydney
“It costs quite a bit of money to run phase one and two studies, and you might be halfway through that when you show your animal has no protection,” Director of the Peter Doherty Institute for Infection and Immunity Sharon Lewin said.
May 15: ‘Testing of COVID-19 skin patch vaccine begun by Verndari Inc. in collaboration with UC Davis,’ The California Aggie
“Before you move [the vaccine] into the human, […] you need to work in multiple animal models, which takes time, to show that not only were you able to show that it’s safe, but that in the event that that individual got infected, it stopped the infection from causing a clinical disease or at least reduced the clinical symptoms,” said Kristin Grimsrud, the associate director of vivaria and veterinary care at UC Davis’ Mouse Biology Program.
May 15: ‘UK researchers hope dogs can be trained to detect coronavirus,’ The Guardian
Research has shown that diseases such as malaria have a distinctive odor and also that respiratory disease can change the body’s odor. Scientists are working to determine if medical detection dogs can detect COVID-19 in humans.
May 14: ‘Pathogenesis and transmission of SARS-CoV-2 in golden hamsters,’ Nature
May 14: ‘From hamsters to baboons: The animals helping scientists understand the coronavirus,’ Scientific American
May 14: ‘SARS lessons for COVID-19 vaccine design,’ ScienceDaily
“The ‘spike’ proteins of both SARS-CoV and SARS-CoV-2 are related and they attach to the same molecule called ACE 2 on human cells to infect people. We now also know through animal experiments with SARS-CoV-2 that neutralising antibodies protect from reinfection,” University of Melbourne professor Kanta Subbarao wrote in an article.
May 14: ‘WSU researchers look to head off COVID-19’s deadly pneumonia,’ WSU Insider
This Washington State University press release announced the development of an antibody that successfully neutralizes protein A9, a protein that triggers inflammation, including severe pneumonia in COVID-19 patients. University researchers discovered the specific role of this A9 protein by doing research with mice and studying the A9 protein in mice. Then they were able to develop an antibody.
May 13: ‘GC Wellbeing finds placenta injection relieves COVID-19 symptoms through animal testing,’ Aju Business Daily
A Korean placenta injection showed positive results in a ferret model.
May 13: ‘UW studying coronavirus’s impact on pets,’ Patch
May 13: ‘Infection of bat and human intestinal organoids by SARS-CoV-2,’ Nature
May 13: ‘Cats with no symptoms spread virus to other cats in lab test,’ The Associated Press
May 12: ‘Respiratory disease in rhesus macaques inoculated with SARS-CoV-2,’ Nature
May 12: ‘Research underway to understand how COVID-19 affects different animal species,’ Scripps Media
BREAKING NEWS: May 12: ‘Unveiling “Warp Speed,” the White House’s America-first push for a coronavirus vaccine,’ Science
The White House will soon announce its “Operation Warp Speed” to speed up the development of a COVID-19 vaccine. “The project, vaguely described to date but likely to be formally announced by the White House in the coming days, will pick a diverse set of vaccine candidates and pour essentially limitless resources into unprecedented comparative studies in animals, fast-tracked human trials, and manufacturing,” the article said.
May 12: ‘Pigs exempted: Study uncovers 48 animal species most likely to get coronavirus,’ Science Times
May 11: ‘Researchers develop promising MERS vaccine, with potential for COVID-19,’ Drug Target Review
“A Korean research team has developed a new vaccine platform using RNA-based adjuvants for the Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), which showed promise in nonhuman primates,” the publication reported.
May 11: ‘New HIV vaccine combination strategy provides better and more durable protection,’ Emory University
“Researchers from the Emory Consortium for Innovative AIDS Research in Nonhuman Primates and their colleagues across North America have shown a new HIV vaccine is better at preventing infection and lasts longer, continuing to protect one year after vaccination. The findings, which are published online today in Nature Medicine, provide important insights for preventing HIV, and the timeliness of the results could also help shape the scientific community’s approach to developing vaccines for COVID-19,” a press release said.
May 9: ‘Animals and COVID-19,’ The Scranton Times-Tribune
“Recent research shows that ferrets, cats and golden Syrian hamsters can be experimentally infected with the virus and can spread the infection to other animals of the same species in laboratory settings,” the Q&A article said.
May 8: ‘From proposals to funded research in 48 hours: Tulane scientists receive Fast Grants,’ Tulane
“Mairi Noverr of Tulane University School of Medicine along with Monica Vaccari and Tracy Fischer of Tulane National Primate Research Center all received Fast Grants for COVID-19 research,” according to the university.
May 7: ‘Vanderbilt University Medical Center and IDBiologics ally in race to develop breakthrough medicines for COVID-19,’ Business Wire
May 7: ‘The latest on the COVID-19 vaccine,’ Extra TV
On May 7, Extra TV’s Billy Bush sat down with Dr. Armand Dorian to discuss the latest headlines surrounding COVID-19. They discussed the University of Oxford’s successful COVID-19 vaccine trials with rhesus macaques. This allowed Oxford University to move into human trials in late April. Watch the Extra TV segment to learn more! Video credit: Extra TV
May 7: ‘Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins,’ Nature
May 7: ‘The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice,’ Nature
May 6: ‘Pitt collaborating with other researchers on nasal spray that could prevent coronavirus infection,’ CBS Pittsburgh
“In animal studies, Q-griffithsin worked against Ebola, hepatitis, MERS, SARS and other viruses,” the report said.
May 6: ‘Rapid development of an inactivated vaccine candidate for SARS-CoV-2,’ Science
May 6: ‘Hoping llamas will become coronavirus heroes,’ The New York Times
May 5: ‘Antibodies from llamas are a promising avenue in fight against COVID-19,’ Laboratory Equipment
BREAKING NEWS: May 5: ‘Belgian, U.S. scientists look to llama in search for COVID-19 treatment,’ Reuters
“A llama called Winter could prove useful in the hunt for a treatment for COVID-19, according to U.S. and Belgian scientists who have identified a tiny particle that appears to block the new coronavirus,” the article said.
May 4: ‘Fauci: No scientific evidence the coronavirus was made in a Chinese lab,’ National Geographic
“Fauci has said that he thinks a final vaccine could be available for general use as early as January, which would break records for the speed at which previous vaccines were developed,” National Geographic reported. “One reason for his confidence is the ‘impressive’ results being seen now in animals tested with a vaccine candidate made by Cambridge, Massachusetts-based Moderna Therapeutics, which brought it into human trials in a record 42 days.”
May 4: ‘San Antonio researchers land $200,000 to develop possible COVID-19 vaccine,’ San Antonio Current
May 4: ‘A coronavirus vaccine project takes a page from gene therapy,’ The New York Times
Researchers at two Harvard-affiliated hospitals have studied their vaccine candidates in mice. The team expects to test for safety in monkeys in about a month.
May 1: ‘COVID-19 antibody testing: Tougher than true/false,’ Knowable Magazine
“Animal research does suggest that SARS-CoV-2 antibodies may appear and confer some immunity,” the article said.
May 1: ‘Impression Healthcare to commence animal testing of CBD drug for COVID-19 related respiratory conditions,’ Small Caps
April 30: ‘Animal health laboratories aid testing for COVID-19 in people,’ Journal of the American Veterinary Medical Association
April 30: ‘Napa company begins testing a potential COVID-19 vaccine,’ Napa Valley Register
“Verndari, Inc. is also in discussions with the California National Primate Research Center at UC Davis to conduct further testing in nonhuman primates,” the article said.
April 30: ‘Verndari begins preclinical testing of COVID-19 vaccine candidate,’ Pharma News Daily
April 30: ‘We found and tested 47 old drugs that might treat the coronavirus: Results show promising leads and a whole new way to fight COVID-19,’ The Conversation
April 30: ‘Old drugs may find a new purpose: Fighting the coronavirus,’ The New York Times
April 30: ‘San Antonio Partnership for Precision Therapeutics awards $200,000 toward COVID-19 vaccine project,’ The University of Texas at San Antonio
“Vaccine development takes a long time. There has to be rigorous testing in different animal models, and then small-scale studies in humans,” said microbiologist Karl Klose, director of the South Texas Center for Emerging Infectious Diseases and professor of microbiology at UTSA. “The process is designed to ensure the safety of the people who take the vaccine. We will learn a lot from this process, including how to use a live vaccine platform to protect against an emerging disease. Hopefully in the future, we can respond quicker with a vaccine against the next pandemic.”
April 29: ‘UC Davis researchers to begin testing coronavirus vaccine patch this week,’ CBS Sacramento
“Verndari, Inc., a biopharmaceutical company based in Napa, will begin preclinical testing of a possible coronavirus vaccine on mice this week in partnership with UC Davis’ mouse biology program,” the report said.
April 29: ‘Research delayed, rodent populations reduced during pandemic,’ Journal of the American Veterinary Medical Association
BREAKING NEWS: April 29: ‘Maine research facility working with mice to develop more COVID-19 testing,’ WGME
“This is gonna be a critical piece. It’s like you can’t fight a war without tanks,” said Dr. Ed Liu, president and CEO of The Jackson Laboratory. “You can’t fight a war, this war, the pandemic, without a model system to test whether the drugs or the vaccines work.”
April 29: ‘Gilead’s remdesivir improves recovery time of coronavirus patients in NIH trial,’ The Washington Post
April 28: ‘Flow Pharma reports Ebola vaccine success and how that directed FlowVax COVID-19 vaccine design,’ Accesswire
“Our article published today shows that a single injection of our Ebola vaccine provided 100% protection for mice exposed to Ebola virus” said Flow Pharma Chief Science Officer Charles Herst, the first author on the article. “By relying on killer T-cells rather than antibodies, FlowVax Ebola is able to attack the nucleocapsid protein located at the center of the virus where antibodies cannot reach. We are taking the same approach with FlowVax COVID-19.”
April 27: ‘In race for a coronavirus vaccine, an Oxford group leaps ahead,’ The New York Times
“Scientists at the National Institutes of Health’s Rocky Mountain Laboratory in Montana last month inoculated six rhesus macaque monkeys with single doses of the Oxford vaccine. The animals were then exposed to heavy quantities of the virus that is causing the pandemic — exposure that had consistently sickened other monkeys in the lab,” the report said. “But more than 28 days later all six were healthy, said Vincent Munster, the researcher who conducted the test.
‘The rhesus macaque is pretty much the closest thing we have to humans,’ Dr. Munster said, noting that scientists were still analyzing the result.”
April 26: ‘KBP begins testing COVID-19 vaccine candidate on animals,’ Owensboro Times
April 25: ‘Coronavirus: In a race against time, vaccine testing expands,’ Mercury News
April 24: ‘New COVID-19 vaccine shows promise in monkeys. Next step: humans,’ Live Science
April 24: ‘Celebrating #WorldImmunizationWeek 2020: #VaccinesWorkforAll,’ Speaking of Research
April 23: ‘A look back at medical advances in 2019 and the role played by animal research,’ European Animal Research Association
BREAKING NEWS: April 23: ‘COVID-19 vaccine protects monkeys from new coronavirus, Chinese biotech reports,’ Science
Beijing-based Sinovac Biotech’s COVID-19 vaccine-in-development showed promise in rhesus macaques, scientists reported.
April 23: ‘Three ways to make coronavirus drugs in a hurry,’ Scientific American
April 22: ‘Statement in support of the global research community’s efforts to end the COVID-19 crisis,’ Speaking of Research
This joint statement is the result of a collaboration between several research advocacy organizations along with individual biomedical researchers, animal care experts and university communicators.
April 20: ‘COVID-19: New animal data back up Gilead’s remdesivir as other treatment candidates emerge,’ FierceBiotech
April 20: ‘Why the new coronavirus affects some animals, but not others,’ Smithsonian Magazine
April 19: ‘PAK1-blockers: Potential therapeutics against COVID-19,’ Medicine in Drug Discovery
“Ciclesonide is used to treat inflammatory disesaes such as asthma and allergic rhinitis. It is marketed under the brand names Alvesco for asthma etc. It was patented in 1990 and approved for adults and children 12 and over by the FDA in 2006,” the article said. “Regarding the molecular mechanism underlying its anti-inflammatory effect, it is most likely that this hormone blocks PAK1, mainly for following reasons: (i) first of all, inflammation in general requires PAK1 , and in PAK1-null mutant of mice no inflammation takes place , (ii) ciclesonide (10 mg/kg/day) almost completely suppresses the PAK1-dependent growth of lung cancer (A541 cell line) xenografts in immune-deficient mice as well , and (iii) this hormone was recently shown to block both PAK1-dependent replication and pathogenesis (fibrosis = lung inflammation) blocks COVID-19 pathogenesis clinically : https://writening.net/page?FC3QPm.”
April 18: ‘Rocky Mountain Labs make advancements in race to combat COVID,’ NBC Montana
“Investigators at Rocky Mountain Labs tested [remdesivir] in a non-human primate model, a SARS-Coronavirus Type 2 or Covid-19,” said RML’s associate director for scientific management, Dr. Marshall Bloom. “They found that this drug had significant affect in ameliorating the course and severity of COVID-19 infections in non-human primates, if given early enough during the course of the disease.”
April 17: ‘Coronavirus: Animal testing may be best tool to defeat COVID-19| Bailey,’ Asbury Park Press
April 17: ‘Investigational chimp adenovirus MERS-CoV vaccine protects monkeys,’ National Institutes of Health
April 17: ‘Remdesivir eases COVID-19 symptoms in monkeys in 12 hours, small preliminary study shows,’ Newsweek
April 16: ‘Scientists at Tulane National Primate Research Center studying vaccines, treatments for COVID-19,’ The Lens
April 14: ‘San Antonio researchers lead the race to create a coronavirus vaccine,’ KENS 5
“We have seven scientists and a staff of over 30 people working overtime on establishing [nonhuman primate] animal models,” Texas Biomed President and CEO Larry Schlesinger said.
April 14: ‘News feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine,’ Proceedings of the National Academy of Sciences of the United States of America
April 14: ‘Why will it take so long to develop a COVID-19 vaccine?’ The Globe and Mail
April 13: ‘Saskatoon based lab’s COVID-19 vaccine in animal testing stage,’ DiscoverMooseJaw.com
April 13: ‘Clinical trials for promising COVID-19 drug underway in north Texas,’ KERA News
“Remdesivir is one of the unique compounds that actually gets stuck and makes the replication complex stop in its tracks,” Dr. Robert Gottlieb told KERA. “It has been used against SARS in vitro, and actually that’s why it became such a good lead compound with the current epidemic. … We’ve studied [SARS-CoV-1] and some similar viruses like [MERS] … both in small animals as well as in larger animals, and this remdesivir seems to work just fine in those cases.”
April 13: ‘Could a 100-year-old vaccine protect against COVID-19?’ Live Science
April 13: ‘UC Davis researchers work toward developing potential vaccine for COVID-19,’ The Aggie
“We learned from [previous research] about basically how to grow this virus, what things might inhibit it, what are some vaccine strategies that could be tried and then we start to think about the biology of this new agent and whether these strategies are applicable,” said Denis Hartigan-O’Connor, an associate professor in the department of medical microbiology and immunology and a core scientist at the California National Primate Research Center.
April 12: ‘The real reason veterinarians gave a tiger a Covid-19 test,’ WIRED
“Veterinary diagnostic labs across the country are developing their own tests for Covid-19, and many use the same basic processes that human tests do,” the article said.
April 10: ‘Animal studies give hope to a future where a pill could prevent COVID-19 infection,’ ABC News
April 9: ‘The COVID-19 vaccine development landscape,’ Nature
“In order to assess vaccine efficacy, COVID-19 specific animal models are being developed, including ACE2-transgenic mice, hamsters, ferrets and non-human primates. Biosafety-level 3 containment measures are needed for animal studies involving live-virus challenges, and the demand for these capabilities is likely to require international coordination to ensure that sufficient laboratory capacity is available,” the article said.
April 8: ‘Flow Pharma announces start of pre-clinical efficacy study for FlowVax COVID-19 vaccine,’ Accesswire
“Flow Pharma, Inc., a San Francisco Bay Area biotechnology company developing the FlowVax(TM) peptide vaccine platform technology, today announced that researchers at the University of Texas Medical Branch at Galveston (UTMB) will begin testing Flow Pharma’s FlowVax COVID-19 vaccine candidate by challenging nonhuman primates with SARS-CoV-2, the virus that causes COVID-19 in humans, after the animals are vaccinated this month with FlowVax COVID-19,” a press release said.
April 8: ‘Auburn’s CPAP-to-ventilator device passes major test on live animal,’ Auburn University
April 8: ‘Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2,’ Science
April 8: ‘Tulane University awarded grant to start studies on COVID-19 vaccines,’ WVUE
April 7: ‘Engineered virus might be able to block coronavirus infections, mouse study shows,’ American Society of Microbiology
April 7: ‘Army researchers start coronavirus vaccine testing on primates at Maryland’s Fort Detrick,’ Baltimore Sun
April 7: ‘New coronavirus drug shows promise in animal tests,’ Scientific American
April 7: ‘Army begins testing possible coronavirus vaccines on primates at Fort Detrick,’ The Hill
April 7: ‘See what it takes to make a vaccine during the coronavirus pandemic,’ The Hill
“When you talk about developing a vaccine for millions of people, safety is an enormous priority,” said Dr. Mark Poznansky, director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital.
April 6: ‘Promising drug on the horizon for COVID-19,’ NPR
Scientists from Emory University in Atlanta; the University of North Carolina at Chapel Hill; and Vanderbilt University Medical Center in Nashville, Tennessee, reported promising results after testing the drug EIDD-2801 on mice infected with coronaviruses similar to the one that causes COVID-19.
April 6: ‘Army researchers begin animal testing of coronavirus vaccine,’ Military.com
April 6: ‘An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice,’ Science Translational Medicine
April 6: ‘Coronavirus patients rush to join studies of Gilead drug,’ The Associated Press
“In animal tests against SARS and MERS, diseases caused by similar coronaviruses, the drug helped prevent infection and reduced the severity of symptoms when given early enough in the course of illness,” the AP reported.
April 6: ‘Scientists around the globe pivot their research to SARS-CoV-2,’ The Scientist
BREAKING NEWS: April 6: ‘Tulane University awarded $10.3 million to test therapeutics, vaccines for novel coronavirus,’ Tulane
The Tulane National Primate Research Center in Louisiana will study COVID-19 in three species of nonhuman primates and evaluate potential COVID-19 vaccines and treatments in the nonhuman primate species that most closely mimics the progression of the disease in a human.
April 2: ‘Coronavirus: Australian scientists begin tests of potential vaccines,’ BBC News
The World Health Organization cleared potential coronavirus vaccines for animal testing. Researchers in Australia have inserted vaccine samples into ferrets. “Australia’s Commonwealth Scientific and Industrial Research Organization (CSIRO) says its tests will be the first comprehensive pre-clinical trials of the vaccines to use an animal model,” the article said.
April 2: ‘Pitt team makes progress on possible COVID-19 vaccine,’ Pittsburgh Post-Gazette
April 2: ‘Pittsburgh scientists develop possible coronavirus vaccine, hope FDA can fast-track it,’ Pittsburgh Tribune-Review
April 2: ‘COVID-19 is interrupting lab animal research, sometimes fatally,’ Popular Science
April 2: ‘Potential COVID-19 vaccine shows promise in mouse study,’ Reuters
A team at the University of Pittsburgh School of Medicine is working on a potential COVID-19 vaccine. It’s shown promise during initial tests in mice, scientists said.
BREAKING NEWS: April 2: ‘Chinese wildlife ban freezes export of test monkeys amid worldwide push for COVID-19 vaccine,’ The Globe and Mail
“A Chinese ban on the sale of wild animals has frozen the export of monkeys used for pharmaceutical research, turning a measure to prevent future outbreaks into a new obstacle in the fight against the pandemic,” article said. “On Jan. 26, the Chinese government temporarily banned the transport and sale of wild animals after a deadly new coronavirus began to spread through a Wuhan market that advertised the sale of live cats, dogs, snakes, rats, foxes, civets, monkeys and other creatures. Less than a month later, China permanently outlawed all trade in wild terrestrial animals, a move praised by international wildlife advocacy groups.”
April 1: ‘Interview with Johnson & Johnson research head: Vaccine development at “turbo speed” – knowledge,’ NewsyList
“We already have a lot of data on the safety of the vaccine candidate, because the necessary preclinical studies in nonhuman primates and animals have already been carried out,” J&J research chief Paul Stoffels said in an interview with the German newspaper Tagesspiegel.
April 1: ‘Texas Biomed receives $3M to expand coronavirus studies,’ Rivard Report
“Researchers will use the funds to amplify efforts to investigate how SARS-CoV-2 – the virus that causes COVID-19 or the novel coronavirus – affects animals. Previously, research was limited to studying the effects on baboons, but now will include macaques, marmosets, mice, and guinea pigs,” the article said.
April 1: ‘Covid-19 changed how the world does science, together,’ The New York Times
April 1: ‘Georgia pharmaceutical lab working on COVID-19 vaccine, waiting on federal funds,’ WGXA
BREAKING NEWS: March 31: ‘Testing to begin in metro Atlanta for COVID-19 vaccines,’ 11Alive News
GeoVax is preparing to test three candidate vaccines for the novel coronavirus in animals, CEO David Dodd says. With funding from the Biomedical Advanced Research and Development Authority, GeoVax will use animal testing to zero in on the vaccine that is most likely to protect people from COVID-19, then scientists will test the most promising of them in clinical trials later this year.
March 31: ‘Israel tests coronavirus vaccine prototype on rodents at defense lab,’ Reuters
March 31: ‘Should pets be tested for coronavirus?’ Science
Veterinarians don’t have evidence that pets can spread SARS-CoV-2, but they want more information, and several labs have developed veterinary tests. Shelley Rankin, a microbiologist at the University of Pennsylvania School of Veterinary Medicine, says if pets were readily susceptible to the virus, a spike would have been noticed by now, and the USDA and many experts warn against widespread testing of pets for COVID-19.
March 30: ‘Trump administration orders $1.8M in coronavirus research monkeys,’ The Daily Beast
BREAKING NEWS: March 28: ‘Louisiana researchers studying monkeys for a coronavirus vaccine face challenges as state cases spike,’ ABC News
Scientists at the Tulane National Primate Research Center in Louisiana are working hard to fight COVID-19. ABC News gave an inside look at the challenges these researchers are up against.
March 27: ‘The US keeps millions of chickens in secret farms to make flu vaccines. But their eggs won’t work for coronavirus,’ CNN
About 82% of the 174.5 million doses of influenza vaccine distributed across the U.S. this season were produced in chicken eggs, according to the CDC, but the many chickens kept in secure facilities in the U.S. won’t be useful in developing a COVID-19 vaccine. Coronaviruses and influenza viruses have different receptors and other characteristics, and the novel coronavirus can’t replicate inside eggs the way influenza can, says pathology professor John Nicholls.
March 26: ‘Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins,’ Nature
BREAKING NEWS: March 26: ‘How monoclonal antibodies might prove useful against the coronavirus,’ NPR
Researchers are studying antibodies to find out how to beat COVID-19. “If the antibodies work to protect cells from infection, then researchers will test them in animals exposed to the virus — to see if the proteins prevent the animals from getting sick, or, alternatively, if they can improve the health of animals that are sick with a version of COVID-19,” the report said.
March 25: ‘Pirbright begins testing new coronavirus vaccines on animals to help combat COVID-19,’ The Pirbright Institute
March 24: ‘When might experimental drugs to treat COVID-19 be ready? A forecast,’ STAT
March 24: ‘Idexx Laboratories tested thousands of pets for coronavirus. None have come back positive,’ Today
March 23: ‘Oxford University prepares for coronavirus vaccine trial,’ pharmaphorum
March 22: ‘WHO launches global megatrial of the four most promising coronavirus treatments,’ Science
“With about 15% of COVID-19 patients suffering from severe disease and hospitals being overwhelmed, treatments are desperately needed. So rather than coming up with compounds from scratch that may take years to develop and test, researchers and public health agencies are looking to repurpose drugs already approved for other diseases and known to be largely safe. They’re also looking at unapproved drugs that have performed well in animal studies with the other two deadly coronaviruses, which cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS),” the article said.
March 22: ‘Africa’s mountain gorillas also at risk from coronavirus,’ The Associated Press
“We know that gorillas are very sensitive to human diseases,” Paula Kahumbu, chief executive of the Kenya-based conservation group WildlifeDirect, told the AP. “If anyone has a cold or a flu they are not allowed to go and see the gorillas. With coronavirus having such a long time of no symptoms in some cases, it means that we could actually put those gorillas at risk.”
March 21: ‘Second dog tests positive for coronavirus as owners warned not to abandon pets,’ MarketWatch
March 21: ‘University of Minnesota is going ‘full-on MacGyver’ against COVID-19,’ Star Tribune
March 20: ‘COVID-19: U of S lab develops animal model for COVID vaccine testing,’ The StarPhoenix
“The University of Saskatchewan’s Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) is the first Canadian lab to develop an animal model for COVID-19 vaccine testing,” the article said.
March 19: ‘Chloroquine, an old malaria drug, may help treat novel coronavirus, doctors say,’ ABC News
Chloroquine phosphate, an 85-year-old antiviral drug that has previously been used for the treatment of malaria, and its derivative hydroxychloroquine have recently shown promising in-vitro results in primate cells infected with SARS-CoV-2. Chloroquine phosphate became the first-choice antiviral drug for malaria after researchers discovered it drastically reduced mortality in African penguins with avian malaria.
March 19: ‘US primate centers work to protect animals from COVID-19,’ The Scientist
Monkeys are vulnerable to SARS-CoV-2. Primate center scientists are working to prevent colonies from infection.
March 18: ‘Coronavirus vaccines: five key questions as trials begin,’ Nature
March 18: ‘HIV drug combo fails as treatment for severe COVID-19 in China study,’ Reuters
Extensive studies in a variety of nonhuman primates, including macaques, led to the development of lopinavir and ritonavir as HIV/AIDS combination anti-retroviral drugs. In 2015, researchers discovered that lopinavir and ritonavir improved outcomes in marmoset monkeys infected with the MERS coronavirus (MERS-CoV). Since SARS-COV-2 and MERS-CoV are both coronaviruses and share many similarities, researchers launched a clinical trial of lopinavir and ritonavir in patients with COVID-19 in China.
March 18: ‘Respirators, quarantines, and worst-case scenarios: Lab animal facilities grapple with the pandemic,’ Science
The heads of two animal facilities spoke with the academic journal about how they are dealing with COVID-19.
March 18: ‘Letter: I know lab animals are crucial in finding a COVID-19 vaccine,’ The Mercury News
March 17: ‘Regeneron says potential Covid-19 drugs could start human tests by early summer,’ STAT
Regeneron has developed hundreds of monoclonal antibody drugs that show potential for treating SARS-COV-2. Regeneron’s antibodies are produced in mice that have been genetically modified to have human-like immune systems.
March 17: ‘Singapore startup testing drug used to treat cats in race to find COVID-19 cure,’ Today
March 16: ‘First person injected with trial coronavirus vaccine in Seattle,’ Forbes
Moderna and NIAID are currently investigating a potential messenger RNA vaccine for the new coronavirus. A clinical trial in humans has begun in Seattle for the mRNA-1273 vaccine. Despite reports to the contrary, the clinical trial began after mRNA-1273 was tested in mice.
March 16: ‘Why animal research is essential to tackling Covid-19,’ Spiked
March 16: ‘As the coronavirus spreads, a drug that once raised the world’s hopes is given a second shot,’ STAT
Gilead Sciences’ antiviral drug remdesivir is currently being tested in five human clinical trials for its effectiveness against the new coronavirus (SARS-CoV-2). Pre-clinical research in laboratory mice and other animals demonstrated that remdesivir was effective against the MERS and SARS coronaviruses.
March 13: ‘Did an experimental drug help a US coronavirus patient?’ Science
Doctors tested remdesivir on a critically ill patient with COVID-19 in California. An infectious disease specialist on the team treating the patient answered questions about the case. In February, Gilead and the National Institute of Allergy and Infectious Diseases (NIAID) published a paper demonstrating that remdesivir inhibited the replication of the coronavirus MERS in infected monkeys.
March 12: ‘Quarantine the cat? Disinfect the dog? The latest advice about the coronavirus and your pets,’ Science
March 11: ‘A virus cure depends on rare lab mice, but there aren’t enough,’ Bloomberg Businessweek
“It’s a basic rule of medical research: Before you inject anything into humans, conduct experiments on animals—frequently mice—to determine whether treatments are safe and effective. In the race to develop a vaccine for the new coronavirus, however, your everyday mouse won’t do,” Bloomberg correspondent Bruce Einhorn wrote.
March 11: ‘CSU researchers are working full-bore on the mysteries of coronavirus — and a vaccine,’ Colorado Public Radio News
March 11: ‘As pressure for coronavirus vaccine mounts, scientists debate risks of accelerated testing,’ Reuters
“Given the urgency to stem the spread of the new coronavirus, some drugmakers are moving straight into small-scale human tests, without waiting for the completion of such animal tests.
‘I understand the importance of accelerating timelines for vaccines in general, but from everything I know, this is not the vaccine to be doing it with,’ Dr Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine, told Reuters.”
March 11: ‘The best hope for coronavirus treatment is an experimental drug that fizzled against Ebola,’ The Washington Post
March 11: ‘Repurposed drugs may help scientists fight the new coronavirus,’ Science News
March 10: ‘How close are biotechs to bringing a COVID-19 treatment to market?’ Benzinga
March 9: ‘LSU School of Veterinary Medicine producing coronavirus vaccines for testing,’ LOCAL 33/FOX 44
Researchers will test potential vaccines in mice.
March 9: ‘Labs rush to study coronavirus in transgenic animals — some are in short supply,’ Nature
March 9: ‘Why a coronavirus vaccine is more than a year away, despite medical researchers’ progress,’ USA Today
Preclinical tests involve research in animals to make sure a vaccine is safe. “If the vaccine protects in animal models, it can be made pure enough to be tested on humans,” Dr. Bart Haynes told USA TODAY.
March 7: ‘Texas baboon troop enlisted in humankind’s war on coronavirus,’ Bloomberg
“Animal research has played a critical role in virtually every medical advance over the last century,” said Matthew R. Bailey, president of the Foundation for Biomedical Research.
March 3: ‘Could GSK reject benefit COVID-19 patients?’ BioWorld
APN01 is a recombinant human Angiotensin Converting Enzyme produced by APEIRON Biologics that successfully blocked viral spread of SARS-CoV-2 and minimized lung injury when tested in laboratory mice. APN01 is now entering the clinical trial phase with COVID-19 patients in China.
March 2: ‘Opinion: Animal rights groups choose coronavirus over your safety,’ The Detroit News
The Detroit News published an opinion editorial written by FBR’s president on the importance of animal research in the search for a vaccine to control the coronavirus outbreak.
Feb. 19: ‘Coronavirus will be studied here in Louisiana at this Northshore primate center,’ WDSU
Feb. 16: ‘“A completely new culture of doing research.” Coronavirus outbreak changes how scientists communicate,’ Science
Feb. 11: ‘UW–Madison researchers lead efforts to understand, thwart new coronavirus,’ UW–Madison News
“We are working together to develop a plan to build out nonhuman primate models to test medical countermeasures such as vaccines and therapeutics,” said David O’Connor, professor at the UW School of Medicine and Public Health. “We want to make sure we are recapitulating the kind of clinical signs (of virus infection) that happen in people.”
Feb. 2: ‘With coronavirus spreading, now is not the time for restrictions on animal research,’ International Business Times